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Abstract
This thesis is a detailed investigation into subcortical changes in Alzheimer’s
disease (AD). Hippocampal volumes, shapes and diffusion metrics were inves-
tigated in different disease stages and presentations, and the ability of these
metrics for disease group classification investigated. A new method for auto-
mated thalamic segmentation using multimodal imaging was developed and
applied to two different datasets.
Hippocampal volumes were found to be disproportionately affected by the
apolipoprotein (APOE) ε4 allele. Hippocampal volumes were also found to be
reduced in subjects with the posterior cortical atrophy variant of AD. These
changes were localized in the hippocampal tail region and hippocampal shape
metrics were found to be superior to hippocampal volumes in differentiating
these subjects from controls.
The manual thalamic segmentation protocol developed was found to have
good reliability, and a template library of thalamic segmentations was gen-
erated for use in automated pipelines. The manual segmentation protocol
used both T1-weighted and diffusion magnetic resonance imaging (MRI) scans
for improved segmentation accuracy. The template library was used for auto-
matic segmentation of the thalamus and leave-one-out cross-validation revealed
good segmentation reliability, better than that reported by the most widely-
used automated thalamic segmentation techniques. The thalami from subjects
from the Alzheimer’s disease neuroimaging initiative (ADNI)-GO/2 datasets,
which includes control subjects, subjects with subjective memory complaints,
with early mild cognitive impairment (EMCI), late mild cognitive impairment
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(LMCI) and AD, were segmented using the automated thalamic pipeline. Sub-
jects with AD and mild cognitive impairment (MCI) were found to have lower
thalamic volumes, as well as lower hippocampal volumes suggesting early tha-
lamic involvement.
Differences in diffusion metrics were found and some diffusion metrics
were associated with subsequently higher atrophy rates. The inclusion of hip-
pocampal and thalamic diffusion metrics, in addition to volumes were found
to improve disease group classification.
In summary, this work in this thesis extends existing knowledge about
how the hippocampi and thalami are affected in Alzheimer’s disease.
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Chapter 1
Thesis aims
Change in volume of whole brains, ventricles and hippocampi are well-
established markers of structural brain degeneration in Alzheimer’s disease
(AD). Whole brain and hippocampal atrophy rates and ventricular expansion
rates are elevated in AD and mild cognitive impairment (MCI) and have been
used as outcome markers in clinical trials of potentially disease-modifying ther-
apies [Fox et al., 2005, Salloway et al., 2009]. Rates of hippocampal atrophy
are usually considered more specific markers of AD progression and have been
shown to differentiate mildly cognitively impaired subjects from healthy con-
trols at an early disease stage [Henneman et al., 2009]. Presentations of AD
are heterogeneous however, and in some variants, such as posterior cortical at-
rophy (PCA) the hippocampus remains relatively spared [Crutch et al., 2012].
In addition, there is evidence that the hippocampi may be affected differently
in subjects who are carriers of the apolipoprotein (APOE) ε4 allele [Agosta
et al., 2009, Geroldi et al., 1999, Lehtovirta, 1995, Pievani et al., 2009], the
biggest genetic risk factor for sporadic AD [van Es and van den Berg, 2009].
In order to quantify changes in volumes using magnetic resonance imaging
(MRI), the structures or regions require segmentation. Baseline and follow-up
scans can then be registered and change in volume can be measured directly
from registered scan pairs using techniques such as the boundary shift integral
(boundary shift integral (BSI)) [Freeborough et al., 1997]. In addition to vol-
ume and volume change, shape metrics can be extracted from brain structures.
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There is evidence that shape metrics provide additional information to volume
that may aid in differential diagnosis [Gerardin et al., 2009].
Most segmentation algorithms require a single imaging modality: T1-
weighted structural MRI scans. Although whole-brain, ventricular and hip-
pocampal volumes are widely used as AD biomarkers, relatively little atten-
tion has been given to the role of other subcortical grey matter structures in
AD. However, there is evidence to suggest that structures such as the parahip-
pocampal gyrus [Braak and Braak, 1995,Echa´varri et al., 2011], amydala [Vogt
et al., 1990, Poulin et al., 2011], thalamus [Braak and Braak, 1991, De Jong
et al., 2008] and putamen [De Jong et al., 2008] also undergo atrophy in AD.
Some of the boundaries of these structures are difficult to distinguish from sur-
rounding tissue on T1-weighted MRI scans meaning the accurate segmentation
of these regions remains a challenge.
It may be that other types of MRI scan which provide complimentary in-
formation on brain structure (such as diffusion tensor imaging (DTI)) improve
the segmentation accuracy of some of these deep brain structures. However,
including more types of scan has the disadvantage of increasing scan time and
hence cost and patient discomfort. Patient discomfort may result in motion
artefacts and although data is routinely discarded from studies due to motion,
a thorough investigation into how this may bias the data is warranted. Fur-
ther, the more scan types required for a segmentation to be successful, the
more likely one of these will have artefacts, such as motion, which will render
the scan unusable.
The aims of this thesis are therefore to:
1. Investigate whether accelerated T1-weighted MRI scans can be used in
place of non-accelerated scans for measuring volume and atrophy rates in
established structural biomarkers of AD and whether bias is introduced
by excluding scans which appear to suffer from motion artefacts.
Hypothesis: That accelerated T1-weighted scans can be used in place of
unaccelerated for measures of brain volume and atrophy and that fewer
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accelerated scans suffer from motion artefacts.
2. To explore in depth the heterogeneity of hippocampal atrophy patterns
in Alzheimer’s disease using existing techniques:
(a) To compare hippocampal and whole-brain atrophy rates in APOE
ε4 carriers and non-carriers and to investigate whether APOE ε4
carriers show disproportionate hippocampal atrophy.
Hypothesis: That not only do APOE ε4 carriers show higher rates
of hippocampal atrophy compared with non-carriers, but that the
hippocampi are disproportionately affected in APOE ε4 carriers.
(b) To investigate if and how the hippocampi of subjects with the PCA
variant of AD are affected using volume and shape metrics.
Hypothesis: That subjects with the PCA variant of AD have re-
duced hippocampal volumes compared with controls and that the
posterior portion of the hippocampus is likely more affected than
the anterior portion (given the that the posterior portion of the
brain is more affected in PCA subjects).
3. To investigate whether automated hippocampal segmentation can be im-
proved upon by using a template library which includes the full extent
of the hippocampal tail.
Hypothesis: That the hippocampal tail also atrophies in Alzheimer’s dis-
ease and that a template library with segmentations that include the full
extent of the hippocampal tail will improve disease group classification.
4. To investigate whether the use of diffusion-weighted imaging in addition
to T1-weighted imaging improves segmentation reliability of the thala-
mus and to generate a template library of thalamic regions for automated
segmentation pipelines.
Hypothesis: That diffusion-weighted imaging provides useful additional
structural information about the thalamus and will improve the reliabil-
ity of thalamic segmentation.
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5. To investigate whether there are thalamic and hippocampal volume and
diffusion differences in:
(a) The earliest stages of sporadic Alzheimer’s disease - subjective mem-
ory complainers and mild cognitive impairment, as well as in estab-
lished Alzheimer’s disease.
(b) Young-onset Alzheimer’s disease.
Hypothesis: That thalamic volumes are reduced in subjects with MCI
and that group differentiation can be improved by including thalamic
and hippocampal diffusion metrics. That thalamic volumes are reduced




In the UK an estimated 850 thousand people are living with dementia [M.
Knapp et al., 2014] whilst globally, the number is estimated to be more than 46
million [Prince et al., 2015]. There is evidence to suggest that the prevalence
of dementia has actually fallen slightly in recent years in some high-income
countries [Langa et al., 2017,Wu et al., 2016], possibly due to improved educa-
tion and lifestyle factors. Increasing life expectancy in these countries means
that the numbers of people living with dementia will continue to rise signif-
icantly nonetheless. Low- and middle-income countries, on the other hand,
have seen a significant rise in the prevalance of dementia in recent years and
the numbers are predicted to continue rising dramatically [Prince et al., 2015].
By 2050, an estimated 131.5 million people will be living with dementia across
the world [Prince et al., 2015].
Dementia is a general term that describes a syndrome which results in a
decline in cognitive function severe enough to affect activities of daily living,
usually associated with progressive neuronal loss. According to the Diagnos-
tic and Statistical Manual of Mental Disorders IV (DSM-IV), dementia is a
syndrome that may be caused or characterized by:
Multiple cognitive deficits, which include memory impairment and at least
one of the following: aphasia, apraxia, agnosia or disturbance in executive
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functioning. Social or occupational function is also impaired. A diagnosis of
dementia should not be made during the course of a delirium. (A dementia
and a delirium may both be diagnosed if the dementia is present at times when
the delirium is not present.)
Alzheimer’s disease is the most common underlying pathology for demen-
tia, accounting for 60-80% of cases followed by vascular dementia, Lewy body
dementia, and frontotemporal dementia [Barker et al., 2002, Wilson et al.,
2012]. A majority of those with Alzheimer’s disease pathology actually have
some form of mixed pathology, such as Alzheimer’s disease together with vas-
cular dementia [Schneider et al., 2007].
Although dementia is typically thought of as a disease of old-age, ap-
proximately 5% of those with dementia are under the age of 65 at symptom
onset [M. Knapp et al., 2014]. Dementia in those under the age of 65 is
known as young-onset dementia with Alzheimer’s disease thought to be the
underlying pathology in 30-35% of cases [Harvey and Skelton-Robinson, 2003].
Although some genetic mutations cause young-onset Alzheimer’s disease, in
the vast majority of cases, there is no known genetic cause.
Previous studies have shown that there is more heterogeneity in symptom
presentation [Barnes et al., 2015] and atrophy patterns in those who are af-
fected by the Alzheimer’s at a younger age [Mendez et al., 2012]. A larger pro-
portion of patients with young-onset Alzheimer’s disease have a non-amnestic
presentation than older-onset cases [Mendez et al., 2012].
Posterior cortical atrophy (PCA) is a clinicoradiological syndrome char-
acterized by impairment of visuoperceptual, visuospatial and other poste-
rior cognitive functions and atrophy of the occipital, parietal and occipito-
temporal cortices [Benson et al., 1988, Crutch et al., 2012]. PCA is most
commonly caused by Alzheimer’s disease (AD) [Alladi et al., 2007, Renner
et al., 2004,Tang-Wai et al., 2004] and is probably the most common atypical
clinical presentation of AD [Dubois et al., 2014a]. Although AD is the most
common underlying pathology in PCA (>80%) [Alladi et al., 2007, Renner
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et al., 2004, Tang-Wai et al., 2004] a number of cases have other underlying
pathologies such as dementia with Lewy bodies (DLB), corticobasal degen-
eration, prion disease and subcortical gliosis [Crutch et al., 2012]. Unlike
typical Alzheimer’s disease (tAD), where memory loss is one of the earliest
and most prominent symptoms, episodic memory function in PCA is initially
relatively well preserved [Mendez et al., 2002,Tang-Wai et al., 2004]. Previous
cross-sectional magnetic resonance imaging (MRI) studies have shown distinct
atrophy patterns in subjects with PCA as compared to tAD with PCA show-
ing greater atrophy in the right occipital cortex compared with tAD subjects
and tAD subjects showing greater atrophy in the left temporal lobe compared
to PCA [Lehmann et al., 2011,Whitwell et al., 2007].
After a diagnosis of Alzheimer’s disease, a person can live for several
years, or even decades, for many of these requiring full-time care. It is a
disease that can be devastating on an individual level. On a global level it
is already having a huge impact on health services and society and as the
number of people affected by the disease continues to grow, it will become an
increasingly pressing burden.
As such, therapies that slow down or stop the disease are urgently needed.
2.2 Biomarkers in Alzheimer’s disease
A biomarker is ‘a characteristic that is objectively measured and evaluated as
an indicator of normal biological processes, pathogenic processes, or pharma-
cologic responses to a therapeutic intervention’ [Atkinson et al., 2001].
Biomarkers are required for accurate diagnoses and for objective measure-
ments to test the effect of putative Alzheimer’s therapies on the brain as well
as for understanding more about disease progression.
In Alzheimer’s disease, there is no single biomarker than can be used for
a definitive diagnosis of AD during life. A definitive diagnosis of AD can only
be made when the hallmark features of the disease - amyloid plaques and neu-
rofibrillary tangles - are identified in the brain, most often using histopathol-
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ogy at post-mortem. This means that in many of the clinical trials that have
taken place to date, a percentage of participants may not have actually had
AD pathology [Jellinger and Attems, 2015]. Another problem clinical trials in
AD have faced is that by the time a person has symptoms of AD , they may
have already lost a substantial amount of brain tissue. Complicating matters
further, it is a disease that can present with a variety of symptoms and the
disease can initially affect different areas of the brain in different individuals.
In order to find an effective treatment for Alzheimer’s disease, it is neces-
sary to test potential disease-modifying therapies in those who genuinely have
AD pathology, to target the disease at a stage when extensive damage has not
already taken place and to take into consideration some of the heterogeneity
in disease presentation when using biomarkers as outcome measures in clinical
trials.
The importance of recognising preclinical AD , in order that individuals
can be targeted at this early stage, before tissue is lost and symptoms are
accrued has resulted in published guidelines [Knopman et al., 2012, Dubois
et al., 2016]. The guidelines in these publications do not establish diagnostic
criteria for preclinical AD , but propose that additional research is undertaken
in order to establish which biomarkers are better able to identify dementia-
related changes in the brain at a preclinical stage.
A number of biomarkers are currently in use in Alzheimer’s disease and
have complimentary roles. Although the focus of this thesis is on structural
brain imaging as well as diffusion tensor imaging, a brief summary of some of
the most common biomarkers in use in Alzheimer’s disease is given below.
2.2.1 Biomarkers of amyloid and tau deposition in the brain
Abnormal levels of amyloid in the brain can be measured using cerebrospinal
fluid (CSF) [Shaw et al., 2009] and positron emission tomography (PET)
scans [Klunk and Mathis, 2008]. Although normal amyloid levels can be
used to exclude those without underlying Alzheimer’s disease pathology, there
are many individuals who are found to have numerous amyloid plaques post-
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mortem who had no other evidence of the disease during life [Dickson et al.,
1992]. Therefore, evidence of amyloid in the brain alone, is not enough for a
diagnosis of Alzheimer’s disease.
Tau protein levels can also be measured in CSF [Blennow et al., 2010],
and, more recently, imaging of tau pathology using PET tracers has become
possible [Villemagne et al., 2015]. Evidence suggests that tau deposition in the
brain is more tightly coupled to neurodegeneration than amyloid. Tau imaging
is still far from being widely available in the clinic however.
2.2.2 Structural brain imaging as a biomarker
MRI plays a key role in diagnosis, research and clinical trials in dementia.
Single time-point structural MRI of the brain allows for the visualisation of
atrophy patterns, which can aid diagnosis in neurodegenerative diseases. Re-
cent diagnostic criteria recommend structural imaging not only to exclude
treatable causes (e.g. tumour) but to support diagnosis (including variants of
AD ) [McKhann et al., 2011, Dubois et al., 2014b, Hyman et al., 2012]. Vol-
umetric MRI allows for quantification of brain volumes. Serial 3D structural
MRI scans of the brain allows for the visualisation and quantification of pro-
gressive tissue loss, which may be helpful in particularly difficult cases, and
notably as objective assessments in clinical trials. Reductions in brain vol-
ume are thought to predominantly reflect neuronal loss in AD. Differences in
hydration can impact brain volume measures however [Duning et al., 2005].
In addition, anti-amyloid trials have reported increased brain volume loss in
antibody responders [Fox et al., 2005] [Vellas et al., 2009]. It is thought that
this loss in volume was due to the removal of amyloid-plaques or changes in
fluid balance, rather than increased tissue loss in these individuals [Fox et al.,
2005].
2.2.2.1 T1-weighted MRI
An example of a T1-weighted MRI scan is shown in the first column of figure
2.1. In T1-weighted MRI scans, grey matter appears grey, white matter ap-
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Figure 2.1: Sagittal, coronal and axial slices of a T1-weighted scan (column 1),
T2-weighted scan (column 2) and coloured fractional anisotropy map
(column 3) through the brain of the same individual. The colours in-
dicate the diffusion direction (red = diffusion along the left-right axis,
blue = diffusion along the inferior/superior axis, green = diffusion along
the anterior/posterior axis.) and intensity is proportional to fractional
anisotropy.
pears as a lighter grey and cerebrospinal fluid appears dark. T1-weighted scans
are useful for visualising atrophy patterns. Examples of T1-weighted scans in
a healthy participant, an individual with mild cognitive impairment and an
individual with AD are shown in figure 2.2. Several visual rating scales have
been developed for assessing levels of atrophy on single time-point T1-weighted
scans [Scheltens and van de Pol, 2012, Koedam et al., 2011]. Volumetric 3D
scans with high resolution and good contrast between grey and white matter
can be acquired for measuring volumes and progressive tissue loss.
2.2.2.2 T2-weighted MRI
An example of a T2-weighted MRI scan is given in the second column of figure
2.1. In T2-weighted scans, CSF appears bright, white matter appears dark
grey, and grey matter appears light grey. T2-weighted scans are useful for
imaging pathology such as oedemas and for assessing white matter damage.
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Figure 2.2: Sagittal, coronal and axial views of T1-weighted MRI scans in a healthy
individual (column 1), an individual with mild cognitive impairment
(MCI) (column 2) and Alzheimer’s disease (AD) (column 3).
T1-weighted scans have been preferentially used for measuring brain volumes
. Recent advances in MRI pulse sequencing has made volumetric T2-weighted
scans feasible only recently [Busse et al., 2008] and so, although it may be
possible to use T2-weighted scans in place of T1-weighted scans for assess-
ment of atrophy, volumetric T2-weighted imaging has a less established role
in Alzheimer’s disease than volumetric T1-weighted imaging.
2.2.2.3 Computer tomography
computer tomography (CT) scans can also be used for visualisation of atrophy
patterns and for exclusion of other causes of cognitive deficits. The contrast
between grey and white matter is much better on MRI scans than CT scans
however, making MRI scans preferable for delineating subcortical structures
in the brain and for longitudinal assessment of brain atrophy patterns. An
additional advantage of MRI scans over CT scans is that MRI scans do not
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expose individuals to ionising radiation.
2.2.2.4 Diffusion tensor imaging
Multiple types of scan with complimentary information can be acquired using
an MRI scanner. In addition to structural MRI scans, such as T1-weighted
or T2-weighted scans, scans that give information about the diffusion of wa-
ter molecules in the brain can be acquired. Diffusion tensor imaging (DTI)
is a type of MRI scan that gives information about the orientation, location
and anisotropy of the brain’s white matter tracts. Metrics such as fractional
anisotropy (FA) and mean diffusivity (MD) can be derived from diffusion ten-
sor imaging, providing measures of altered tissue structure. FA represents the
degree of diffusion anisotropy and is a scalar value between 0 and 1, where 0
represents isotropic diffusion (unrestricted in all directions) and 1 represents
diffusion along only one axis. FA is a measure of microstructural integrity and
reflects a number of tissue properties such as axonal count and density, degree
of myelination and fibre organization [Winston, 2012]. MD, also a scalar value,
represents reflects the rate of water diffusion within a voxel, independent of
direction. Diffusion weighted imaging has a number of limitations such as it’s
relatively low resolution and it’s inability to correctly characterise diffusion
in areas where there is a complex fibre architecture. For example, in a voxel
where fibres cross, the FA would be lower than in a voxel where there are
fibres oriented in only one direction [Van Hecke et al., 2016]. An example of
a coloured FA map, showing both the magnitude and direction of diffusion of
water molecules in the brain, is given in column 3 of figure 2.1.
Differences in DTI metrics have been shown in AD when compared to
controls [Canu et al., 2012] and may even precede volume loss [Douaud et al.,
2011]. Previous work has shown that the addition of DTI metrics to grey mat-
ter morphometry in the hippocampus and parahippocampal gyrus improved
the ability to distinguish AD subjects from controls [Kantarci et al., 2010].
Other work has shown reduced white matter volumes and fractional anisotropy
in the parahippocampal gyrus in AD patients [Wang et al., 2012,Kalus et al.,
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2006] and in MCI [Rose et al., 2006] suggesting that disruption in flow of












33Figure 2.3: Baseline and month 36 follow-up scan. The first row shows unregistered follow-up scan and the difference between the baseline
and unregistered follow-up. The second row shows the follow-up scan affinely registered to the baseline and the difference
between baseline and registered follow-up scans. By registering the follow-up scan to the baseline, tissue loss can be localised
and quantified using the boundary shift integral.
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2.2.3 Neuropsychology
Cognitive deficits of Alzheimer’s disease can be assessed using neuropsycho-
logical tests. Results from these assessments are usually primary outcome
measures for clinical trials. Although somewhat subjective, they theoretically
more closely associate with symptomatic loss of skills and increase in deficits
experienced by patients. Neuropsychological tests have a number of limita-
tions. For example, the mini-mental state exam (MMSE) [Folstein et al.,
1975], widely-used in research and the clinic suffers from floor and ceiling ef-
fects. The MMSE assigns individuals a score out of 30. Controls and those
at the early stages of the disease often score 30 on this test. In addition, test
scores such as the MMSE, which is biased towards memory testing, may not
accurately capture disease severity in individuals who have atypical forms of
Alzheimer’s disease where memory problems are less likely to be apparent.
2.2.4 Genetics
Although only a small percentage of Alzheimer’s disease cases have a known
genetic cause, there are a number of genes that increase the likelihood of devel-
oping sporadic Alzheiemer’s disease. Arguably, the most important genetic risk
factor for sporadic AD is the ε4 variant of the apolipoprotein (APOE) gene [van
Es and van den Berg, 2009]. Of the three common alleles of the APOE gene,
ε3 is most frequent with ε4 less common and ε2 relatively rare [Eisenberg
et al., 2010]. The ε4 allele increases the risk of AD and lowers the age of
disease onset [Corder et al., 1993]. There is also evidence that the topography
of atrophy in ε4 carriers (ε4+) may be different from non-carriers (ε4-) in
AD [Agosta et al., 2009, Geroldi et al., 1999, Lehtovirta, 1995, Pievani et al.,
2009] although not all studies have confirmed this [Drzezga et al., 2009].
2.2.5 Ordering of biomarker changes in Alzheimer’s disease
Changes in biomarkers occur a different disease stages. A hypothetical model
for the ordering of biomarker changes in Alzheimer’s disease is given in [Jack
et al., 2013].
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Changes in levels of amyloid in the brain are thought to be the earliest
sign of Alzheimer’s disease. Abnormal levels of amyloid occur before the loss
of brain tissue and possibly many decades before symptom onset. These levels
likely approach plateau at an early stage in the disease course [Jack et al., 2013],
so may not be the most suitable biomarkers for tracking disease progression
once the disease is manifest. This is closely followed by abnormal levels of the
tau protein.
Increased brain atrophy occurs after the deposition of amyloid and tau in
the brain, but years before clinical onset [Dickerson et al., 2011]. Volumetric
MRI scans are therefore ideally placed for tracking disease progression.
Clinical symptoms and cognitive deficits of Alzheimer’s disease are
thought to become apparent only after the brain starts to atrophy. Neuropsy-
chological tests in Alzheimer’s disease are useful diagnostic tools of manifest
disease, but are less well placed for disease tracking at an early stage.
2.3 Measuring volumes and volume change using MRI
scans
In order to measure regional volumes and to quantify changes in volumes using
MRI , the structures or regions require segmentation.
2.3.1 Manual segmentation
Manual segmentation is considered the gold standard technique for region seg-
mentation, however, current databases of patients and control subjects are of
a size (total ADNI2 dataset > 700 subjects with multiple scans) where such
practices are difficult to implement for the whole study. This problem can be
circumvented by using a large number of manual segmentors, however, training
can take three months and inter-rater variability may confound the results. In
addition, manual segmentations are not always accurate - humans make errors.
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2.3.2 Automated segmentation
Some of the most widely-used techniques for automated subcortical brain
structure segmentation are atlas-based (FIRST, freesurfer) [Patenaude et al.,
2011, Fischl et al., 2002], where a manually labelled brain atlas or atlases are
non-linearly warped to the unsegmented target image and the labels are used
segment the target brain. Various combinations of different types of atlas
(topological [Collins et al., 1998], probabilistic [Shattuck et al., 2008, Ham-
mers et al., 2003]), registration techniques and segmentation strategies (label
propagation [Iosifescu et al., 1997, Fischl et al., 2002], multi-atlas label prop-
agation [Aljabar et al., 2009], probabilistic atlas-based segmentation [Awate
et al., 2006] etc) are employed in the different segmentation algorithms. The
segmentation accuracy of atlas-based algorithms is dependent on the quality
of the manual segmentations used in the atlases, as well as the variety of mor-
phology represented in the atlas database and the types of pathologies under
investigation. Most existing automated subcortical segmentation methods rely
on manual segmentation of T1-weighted images to create the atlases used in
such algorithms. However, since not all boundaries of subcortical structures
are clearly visible on T1-weighted scans, the manual segmentation accuracy is
limited as is the accuracy of the resulting automated subcortical segmentation
methods based on these T1-weighted atlases.
2.3.3 Indirect measures of change
Volume change between two scans can be measured indirectly by segmenting
the structure of interest on the follow-up and baseline scans, measuring the
volume at each time point and subtracting one from the other. The problem
with measuring atrophy with this method is that the measurement errors (in
the segmentation) can be of the order of the volume changes being measured.
2.3.4 Direct measures of change
Volume change can be measured directly by registering baseline and follow-up
scans. Change in volume can be measured directly from registered scan pairs
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using techniques such as the boundary shift integral (BSI) [Freeborough et al.,
1997]. The boundary shift integral reduces the measurement errors by using
the segmentations at baseline and follow-up to register the structure of interest
and then calculates how much the boundary of the structure of interest has
shifted using intensity windowing directly on the voxel intensities. A graphical
representation of the BSI is shown in figure 2.4.
Figure 2.4: The BSI determines the change in volume directly from voxel intensi-
ties on registered pairs of MRI scans. Hypothetical intensity profiles of
baseline and follow-up scans are shown along a line through the brain
boundary. The green hatched area represents the BSI on both the graph
and the image of a brain.
Another direct method for measuring change in brain volume is SIENA
(Structural Image Evaluation, using Normalisation, of Atrophy) [Smith et al.,
2002]. In this method, brain regions are automatically extracted from baseline
and follow-up scans and they are then registered. The surface motion (between
the two time points) is estimated at brain surface points, to subvoxel accuracy.
A percentage brain volume change estimate can then be calculated from the
mean perpendicular edge motion across the entire brain surface. This method
of measuring brain volume change has been shown to have strong correspon-
dence to the BSI [Smith et al., 2007].
Non-linear registration methods can also be used to measure brain volume
change directly [Boyes et al., 2006]. In these methods, an affine registration is
followed by a non-linear registration. From the non-linear registration, jaco-
bian matrices for each voxel are obtained. The determinant of each of these
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matrices represents the expansion or contraction of each voxel. These can then
be integrated over a brain region to produce an estimate of atrophy.
By treating the baseline scan as a reference scan for follow-up scans, some
techniques for measuring brain volume change directly have been found to be
biased and show asymmetry. A number of techniques for ensuring symmetrical
measures of atrophy have since been employed [Fox et al., 2011].
A head-to-head comparison of various direct methods for measuring vol-
ume change over time and an assesment of their bias is reported in [Cash et al.,
2015].
2.3.5 Structures commonly segmented in AD
Although whole-brain, ventricular and hippocampal volumes are widely-used
as AD biomarkers, little attention has been given to the role of other subcortical
grey matter structures in AD but there is evidence to suggest that structures
such as the parahippocampal gyrus [Braak and Braak, 1995, Echa´varri et al.,
2011], amydala [Vogt et al., 1990, Poulin et al., 2011], thalamus [Braak and
Braak, 1991, De Jong et al., 2008] and putamen [De Jong et al., 2008] also
atrophy in AD. Some of the boundaries of these structures are difficult to
distinguish from surrounding tissue on T1-weighted MRI scans meaning the
accurate segmentation of these regions remains a challenge.
2.3.6 Multimodal segmentation: a way of investigating subcor-
tical structures?
Different MRI modalities provide complimentary information about tissue
properties and its microstructure including DTI. Subcortical regions, such
as the thalamus, have well-structured fibre connections to defined cortical
and subcortical areas. DTI allows the delineation of axonal tracts within
white matter, unlike T1-weighted MRI. As a result, DTI imaging may offer
enhanced intrinsic contrast in some subcortical areas such as the thalamus.
Incorporation of DTI into manual segmentation protocols may allow for more
accurate segmentations of subcortical regions and sub-regions by combining
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information from DTI and T1-weighted scans. Indeed fusion of DTI and T1
weighted scans has shown promising results for the improvement of the seg-
mentation of grey matter, white matter and cerebrospinal fluid (CSF) [Awate
et al., 2008]. In addition, several reports have demonstrated techniques for
segmenting sub-regions of the thalamus [Mang et al., 2012, Behrens et al.,
2003,Jbabdi et al., 2009,Johansen-Berg et al., 2005,Unrath et al., 2008,Wiegell
et al., 2003b, Ziyan et al., 2006, Ziyan and Westin, 2008] and the sub-regions
of the amygdala [Solano-Castiella et al., 2010, Solano-Castiella et al., 2011]
using information from DTI. These techniques focused on the segmentation of
sub-regions however and used masks (either manually or automatically gen-
erated) based on T1-weighted scans to define the limiting outer boundaries
of those structures. Only one study to date has used information from both
T1-weighted scans and DTI scans to automatically segment subcortical struc-
tures [Marrakchi-Kacem et al., 2010]. This study describes a hybrid multicon-
trast deformable model segmentation algorithm that incorporates information
from both T1-weighted and DTI scans. They reported increased segmentation
accuracy when including information from DTI into the algorithm but only
compared the segmentation results with and without DTI data to manual seg-
mentations performed on T1-weighted scans alone. Whether information from
both DTI and T1-weighted MRI scans can be successfully combined to improve




3.1.1 Alzheimer’s disease neuroimaging initiative (ADNI)
Data used in chapters 4, 7 and 9 were downloaded from the ADNI database
(adni.loni.usc.edu). The ADNI was launched in 2003 as a public-private part-
nership, led by Principal Investigator Michael W. Weiner, MD. The primary
goal of ADNI has been to test whether serial magnetic resonance imaging
(MRI), positron emission tomography (PET), other biological markers, and
clinical and neuropsychological assessment can be combined to measure the
progression of mild cognitive impairment (MCI) and early Alzheimer’s disease
(AD). For up-to-date information, see www.adni-info.org. Participants
underwent baseline and periodically repeated clinical and neuropsychomet-
ric assessments and MRI. Detailed inclusion criteria for the ADNI study can
be found at http://www.adni-info.org/Scientists/doc/ADNI_
Protocol_Extension_A2_091908.pdf.
There are several phases to the ADNI study. ADNI-1 was the first phase of
the ADNI study. Participants with mild AD, MCI and controls were enrolled
in this phase of the study and most subjects recruited in this phase of the study
were scanned on 1.5T MRI scanners. ADNI-GO was the second phase of the
ADNI study. In this phase, as well as continuing to collect data from subjects
recruited as part of ADNI-1, 200 subjects with early mild cognitive impairment
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(EMCI) were recruited and were scanned using 3T MRI scanners. ADNI-2
was the third phase of the ADNI study. In this phase new controls, EMCI,
late mild cognitive impairment (LMCI) and mild AD subjects were recruited
and scanned on 3T scanners. Wechsler Memory Scale Logical Memory II
scores (adjusted for years of education) were used to define individuals with
MCI as early or late MCI. For details see http://www.adni-info.org/
Scientists/doc/ADNI2_Protocol_A3_17Oct2014_CLEAN.pdf.
3.1.2 Young onset Alzheimer’s disease (YOAD)
The patients in this cohort were recruited prospectively from a specialist Cog-
nitive Disorders clinic between 2013 to 2015. A total of 45 patients, who all
had a symptom onset at less than 65 years and who met consensus criteria for
probable AD [McKhann et al., 2011] were recruited. None had a known muta-
tion or family history suggestive of autosomal dominant inheritance. Patients
were classified as having a typical [McKhann et al., 2011] or atypical (pos-
terior cortical atrophy) [Tang-Wai et al., 2004]) AD phenotype according to
published criteria. One patient had an atypical frontal variant of Alzheimer’s
disease. 24 age- and gender- matched control subjects were also recruited.
3.1.3 AVID cohort
The patients in this cohort were recruited as part of a pilot study to demon-
strate brain amyloid using Florbetapir F18, between 2012 and 2013. A total
of 22 participants were recruited, with a range of pathologies: 5 with seman-
tic dementia (SD), 5 with posterior cortical atrophy (PCA), 3 with logopenic
aphasia (LPA), 4 with progressive nonfluent aphasia (PNFA) and 5 healthy
age-matched controls.
3.1.4 Posterior Cortical Atrophy cohort
124 subjects were identified retrospectively from a clinical database at the De-
mentia Research Centre (PCA (n=47), typical AD (tAD; n=29), and control
subjects (n=48)). All subjects have been described in a previous study of grey
matter volume and cortical thickness in PCA and typical Alzheimer’s disease
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(tAD) [Lehmann et al., 2011]. Subjects required at least one T1 weighted
volumetric MRI scan to be included in the study. All PCA patients fulfilled
the clinical criteria for posterior cortical atrophy proposed by [Mendez et al.,
2002] and [Tang-Wai et al., 2004] and more recent [Dubois et al., 2014a] cri-
teria for atypical AD, including evidence of posterior cortical dysfunction on
neuropsychological assessment and atrophy on MRI. In addition subjects were
only included in the PCA group if there was no indication of another un-
derlying pathology (such as dementia with Lewy bodies (DLB)). Although the
neuropsychological tests completed were not identical across all individuals, all
PCA patients showed evidence of deficits (scored <5th percentile) in at least
two tasks sensitive to parietal dysfunction - object perception (VOSP Object
Decision test [Warrington and James, 1991b,Warrington and James, 1991a]),
spelling (Graded Difficulty Spelling test [Baxter and Warrington, 1994]), space
perception (VOSP Number Location test [Warrington and James, 1991b]) and
calculation (Graded Difficulty Arithmetic test [Jackson and Warrington, 1986])
- and had relatively preserved episodic memory (>5th percentile on verbal and
or visual Recognition Memory Tests [Tosun et al., 2016, Warrington, 1996]).
Those included in the typical AD group fulfilled revised NINCDS-ADRDA cri-
teria for probable AD [Dubois et al., 2007,McKhann et al., 1984] and had sig-
nificant episodic memory impairments (namely gradual and progressive change
in memory function, objective evidence of significantly impaired episodic mem-
ory, and presence of medial temporal lobe atrophy) with episodic memory im-
pairments quantified as performance <5th percentile on the verbal and visual




The ADNI-1 MRI protocol used in this study is described elsewhere [Jack
et al., 2008]. Most participants in this phase of the study were scanned on
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1.5T scanners. Two (unaccelerated) T1-weighted MRI scans (Magnetization
Prepared RApid Gradient Echo (MPRAGE)) were acquired at each session.
The image of highest quality (as assessed by a single quality control centre)
was selected. Pre-processing corrections were then applied depending on the
scanner manufacturer and head coil used: 1) correction for image geometry
distortion due to gradient non-linearity (gradwarp) [Jovicich et al., 2006], 2)
B1 non-uniformity correction [Narayana et al., 1988] and 3) intensity non-
uniformity correction (N3 histogram peak sharpening) [Sled et al., 1998]. All
pre-processing was performed by the Mayo clinic before being downloaded
locally. After pre-processing, the scans were additionally visually inspected at
the Dementia Research Centre for motion artefacts.
3.2.1.2 ADNI-GO/2
Some changes to the imaging protocol used were made in the ADNI-GO and
-2 phases of the ADNI study. Participants enrolled in this phase of the study
were scanned on 3T scanners. All participants had both accelerated and non-
accelerated T1-weighted MRI scans acquired at each session. Those who were
scanned on GE scanners also had diffusion weighted imaging scans acquired.
Details of imaging protocols can be found at http://adni.loni.usc.
edu/methods/documents/mri-protocols/. The same pre-processing
corrections applied to ADNI-1 scans, described above, were applied to ADNI-
GO and -2 scans.
3.2.2 YOAD
All subjects were scanned on a single Siemens Magnetom Trio 3T MRI scan-
ner using a 32-channel phased array head coil. 3D MPRAGE T1-weighted
volumetric MRI was acquired for each participant (acquisition time 9min 23s,
echo time (TE)/TR/TI = 2.9/2200/900ms, dimensions 256 x 256 x 208, voxel
size 1.1 x 1.1 x 1.1mm). Two identical diffusion-weighted imaging acquisitions
were performed using a single-shot, spin-echo echo planar imaging sequence
(64 diffusion-weighted directions, b = 1000 s/mm2; 9 b = 0 s/mm2 images
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(referred to as ‘b0’ images); 55 slices; voxel size 2.5 × 2.5 × 2.5 mm3; TR/TE
= 6900/91 ms; ).
3.2.3 AVID
MRI scans were acquired on a single 3T Siemens TIM Trio scanner using
a 32-channel phased array head-coil. Anatomical data included a sagit-
tal 3D MPRAGE T1-weighted volumetric MRI (acquisition time 9min 23s,
TE/TR/TI = 2.9/2200/900ms, dimensions 256 x 256 x 208, voxel size 1.1 x 1.1
x 1.1mm) and a coronal T2 Fluid-Attenuated Inversion Recovery (FLAIR) se-
quence (TE/TR/TI = 87/9000/2500ms, voxel size of 0.9375 x 0.9375 x 5mm).
Two identical diffusion-weighted imaging acquisitions were performed using a
single-shot, spin-echo echo planar imaging sequence (64 diffusion-weighted di-
rections, b = 1000 s/mm2; 9 b = 0 s/mm2 images (referred to as ‘b0’ images);
55 slices; voxel size 2.5 × 2.5 × 2.5 mm3; TR/TE = 6900/91 ms; ).
3.2.4 Posterior cortical atrophy
T1 weighted volumetric MR scans were acquired for all subjects on 1.5T Signa
scanners (General Electric, Milwaukee). All scans used an inversion recovery
sequence and all but 7 of the scans consisted of 124 contiguous 1.5 mm coronal
slices through the head. The remaining 7 consisted of 120 contiguous 1.5
mm coronal slices (5 PCA subjects and 2 tAD subjects). Since this was a
retrospective cohort, there was some variation in the scan parameters and
in-plane resolutions of the MRI scans; See Table 3.1 for a breakdown of the
imaging parameters by diagnostic group. The majority of subjects in each
diagnostic group had an in-plane resolution of 0.9 mm x 0.9 mm (including all
7 subjects with 120 coronal slices).
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Table 3.1: MRI scan parameters by diagnostic group
MRI parameters Controlsa (n=48) PCA (n=47) tAD (n=29)
field of view (FOV) (mm) 200 - 280 200 - 280 200 - 280
TR(ms) 11.7 - 15 11.7 - 15 13.6 - 15
TE (ms) 4.2 - 5.4 4.2 - 6.4 4.2 - 5.4
TI (ms) 650 650 650
Flip angle (degree) 13 - 20 13 - 20 15 - 20
% Phase FOV 75 - 100 75 - 100 75 - 100
Slice thickness (mm) 1.5 1.5 1.5
No. of subjects by
in-plane resolution (mm)
0.9 x 0.9 35 31 21
1.1 x 1.1 4 1 3
0.8 x 1.0 7 14 5
0.8 x 1.3 0 1 0
a Scan parameters not available for 2 subjects.
3.3 Image processing
3.3.1 Diffusion processing pipeline
In order to generate fractional anisotropy and mean diffusivity maps from the
acquired diffusion weighted images (diffusion weighted imaging (DWI)s) the
following steps were taken. An iterative groupwise registration and averaging
of the B=0 images was performed using NiftyReg [Modat et al., 2010], followed
by registration of individual DWIs to the average B=0 image (for motion/eddy
current correction) and B vectors adjusted for rotation. Echo-planar imaging
(EPI) susceptibility distortion correction was performed using the field map
images [Daga et al., 2013], and all DWI and B=0 images resampled to the
average B=0 space in a single step using a composition of the registration
and susceptibility correction transforms. Finally, tensor fitting was performed
using weighted least squares fitting implemented in NiftyFit [Melbourne et al.,
2016].
An intracranial mask was generated for the T1-weighted scans using
SPM12’s segmentation toolbox and combining grey matter, white matter and
cerebrospinal fluid classes. This was propagated to the average B=0 space by
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affine registration of the T1 and the B=0 image upsampled to 1.5mm isotropic
using NiftyFit, followed by nonlinear registration of the mask to the average B0
and combination of the affine and non-linearly transformed masks (to ensure
complete brain coverage before and after susceptibility correction). This mask
was then used during the susceptibility correction and tensor fitting steps.
To produce diffusion images matching the T1 image, the fitted diffusion
tensor and average B=0 images were resampled using the inverse of the T1 to
B=0 affine registration. Diffusion metrics for the T1 space were derived from
the resampled tensor volume.
3.4 Brain region segmentation
3.4.1 Brains
Brain regions were delineated by Multi-Atlas Propagation and Segmenta-
tion (Multi-Atlas Propagation and Segmentation (MAPS)) [Leung et al.,
2011]. The whole-brain MAPS technique uses a template library of semi-
automatically segmented whole-brain regions (comprised of grey and white
matter containing voxels with the brain-stem included up until the most infe-
rior slice containing cerebellum). The MAPS technique works by comparing
the target image to these templates and the best-matched templates are then
combined to generate the segmentation of the target image. Segmentations
were performed in native space.
3.4.2 Ventricles
Ventricles (including the temporal horn and excluding the third and fourth
ventricles) were segmented using a semi-automated technique. First the scans
were registered to standard space (using a 9-dof-6 approach: 9 degrees of free-
dom (dof) registration from which the rigid body transform is extracted and
applied to image). An upper threshold of 60% of the mean brain intensity
was then applied to separate brain tissue from the cerebrospinal fluid. Man-
ual editing was then performed to delineate the ventricular boundaries where
required.
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3.4.3 Hippocampi
Two methods were used for automatic hippocampal segmentation in this the-
sis. Both methods use the same template library of 110 manually segmented
hippocampi (right and left from 55 subjects), unless otherwise stated. Details
of the template library used is given in [Barnes et al., 2008]. In both methods,
baseline scans are first registered to standard space and any follow-up scans
are then affinely registered to their baseline.
3.4.3.1 hippocampal multi-atlas propagation and segmentation
(HMAPS)
HMAPS [Leung et al., 2010a], or hippocampal multi-atlas propagation and
segmentation, then uses non-linear registration of the best matched templates
from the template library to generate multiple segmentations, and combines
them using the STAPLE [Warfield et al., 2004] algorithm.
3.4.3.2 Similarity and Truth Estimation for Propagated Seg-
mentations (STEPS)
The STEPS, or similarity and truth estimation for propagated segmentations,
pipeline is an improvement to the HMAPS pipeline described above [Cardoso
et al., 2013]. Rather than using a global metric for ranking similarity, as
HMAPS does, a local similarity metric on a voxel-by-voxel basis is used for
improved segmentation accuracy.
3.4.4 Total intracranial volume
Total intra-cranial volume (total intracranial volume (TIV)) was esti-
mated by summing the volumes of grey matter, white matter, and cere-
brospinal fluid (cerebrospinal fluid (CSF)) segmentations using SPM8
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8). Brain-to-TIV ratio was
calculated by dividing the extracted whole-brain volumes by the extracted
TIVs.
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3.5 Volume change measurement
3.5.1 Brains
For whole brain volume change, follow-up scans were registered to the baseline
scans using affine registration (12dof) and differential bias correction was ap-
plied. Volume change between follow-up and baseline was calculated using the
robust boundary shift integral (robust boundary shift integral (KN-BSI)) [Le-
ung et al., 2010b].
3.5.2 Ventricles
Likewise, for measuring ventricular volume change, follow-up scans were reg-
istered to the baseline scans (which were registered to standard space prior
to segmentation) using affine registration (12dof). Volume change between
follow-up and baseline was calculated using the fixed window boundary shift
integral (BSI) for the ventricles [Freeborough et al., 1997].
3.5.3 Hippocampi
Local 6-dof registration was performed separately for left and right side hip-
pocampi after segmentation using the hippocampus regions dilated by 2 voxels.
Volume change between follow-up and baseline was calculated using the double
window BSI for the hippocampi [Leung et al., 2010b].
3.6 Software
3.6.1 For manual or semi-automated region segmentation
MIDAS (Medical Information Display and Analysis System) software [Free-
borough et al., 1997] was used for manual segmentations of brains, ventricles
and hippocampi used in some of the chapters in this thesis. This software
allows for the simultaneous multi-planer display of 3D data.
NiftyMIDAS, a new software tool under development by the Centre for
Medical Image Computing at UCL, was used for the manual segmentation of
the thalami in this thesis. In addition to being able to view 3D data in all 3
planes, this software also allows for the simultaneous segmentation of multi-
3.6. Software 49
modal data. This feature was utilised for the manual thalamic segmentations,
where T1-weighted and fractional anisotropy maps were simultaneously dis-
played and segmented.
3.6.2 Stata
Stata version 12 (Stata Corporation, College Station, TX, USA) was used for
most of the statistical analyses performed in this thesis.
3.6.3 Matlab
Matlab (matrix laboratory) was used, in conjunction with the SurfStat [Wors-
ley et al., 2009] toolbox for statistical shape analysis in chapter 6.
Chapter 4
Assessment of image quality in
accelerated T1-weighted scans
4.1 Introduction
Atrophy rates, as measured using the boundary shift integral (BSI) have been
shown to be sensitive biomarkers of Alzheimer’s disease (AD) and have been
used as outcome measures in a number of clinical trials [Fox et al., 2005,Jack
et al., 2008, Salloway et al., 2014]. However, the quality of each scan in the
longitudinal series is important to provide robust and accurate results. Poor
quality scans can be caused by patient-related factors such as movement during
the scanning process.
A typical 3T 3D structural brain magnetic resonance imaging (MRI) with
1 mm resolution takes approximately 9 minutes but some subjects have dif-
ficulty remaining still for this time period, often resulting in unusable scans.
Acquisition times can be reduced by employing parallel imaging techniques
(e.g. with scan times 5 minutes), potentially reducing motion artefacts, scan-
ning costs, as well as increasing patient comfort and compliance. Reducing
scanning time may mean that a higher proportion of subjects recruited to a
study or clinical trial have usable MRI scans.
However, accelerated acquisitions alter scan characteristics such as signal-
to-noise ratio, noise distribution and tissue contrast. Before accelerated T1
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scans can be used in place of unaccelerated T1 scans in clinical trials, it is
essential that we understand how accelerated acquisitions may affect cross-
sectional volumes and longitudinal atrophy rate measures. In addition, despite
poor quality MRI scans routinely being excluded from studies (for reasons such
as head coil failure, geometric distortions or patient motion), the question of
whether subject characteristics differ between those who have usable MRI
scans with those who have poor quality scans (due to patient motion) needs
to be evaluated.
Therefore, the aims in this study were to: 1) compare whole brain, ven-
tricular and hippocampal volumes at baseline and atrophy rates (measured
using the BSI) over 6-month and 12-month intervals in accelerated and unac-
celerated scans, 2) investigate whether there was a difference in the number
of good quality accelerated and unaccelerated scans, 3) assess whether subject
characteristics differed between subjects whose scans were considered unusable
due to motion compared with those whose scans were of good quality and 4)
compare estimated sample size requirements for a hypothetical clinical trial
when using accelerated and unaccelerated scans.
4.2 Materials and Methods
4.2.1 Image data and acquisition
Data used in this chapter were downloaded from Alzheimer’s disease neu-
roimaging initiative (ADNI) (as described in 3). ADNI-GO and ADNI-2 in-
cluded both accelerated and non-accelerated acquisition protocols for each par-
ticipant. At the time of downloading baseline MRI scans were available for
a total of 884 subjects, 6 month scans for 572 subjects, and 12 month scans
for 384 subjects. All subjects used in the preparation of this chapter were
scanned on 3T scanners and were new recruits to ADNI-GO/2. Image pre-
processing included post-acquisition correction of gradient warping [Jovicich
et al., 2006] and intensity non-uniformity correction using N3 [Sled et al.,
1998] and SPM5 with tissue priors from a custom template consisting of 400
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elderly subjects (200 NC and 200 AD) from the first phase of ADNI. Scanners
from three different manufacturers (Philips, Siemens and General Electric)
were in use across the different sites. The three different scanner manufactur-
ers use different acceleration protocols; details of the various MRI protocols
are listed on the ADNI website (http://adni.loni.usc.edu/methods/
documents/mri-protocols/). Non-accelerated scans were always ac-
quired prior to the accelerated scans during the same scanning session. Subject
demographics for all subjects with both accelerated and non-accelerated scans
available at baseline, 6- and 12- months are shown in Table 4.1.
4.2.2 Quality control (quality control (QC)) of MRI scans
First, imaging sites were instructed to immediately assess the quality of T1
weighted scans and to re-acquire if necessary; therefore in some cases more
than one accelerated or non-accelerated T1 weighted scan was acquired in a
particular session. QC was performed on all MRI scans at the Mayo Clinic
before being released for download. This QC procedure entailed assessment of
MRI scans for adherence to the ADNI scanning protocol, medical abnormalities
and severe artefacts (such as metal-induced artefacts, head-coil failure etc.).
Only scans that passed this initial QC are available for download and so all
analyses in this paper were only performed on the subset that passed initial
QC by Mayo. At the dementia research centre (DRC), UCL, further quality
assessment of the MRI scans available to download was performed: individual
scans were assessed visually for artefacts and very poor quality scans were
excluded from further analysis (e.g. due to severe motion artefacts); once the
scans were segmented and scan pairs registered (as detailed below), a single
rater (EM), blinded to BSI values, assessed the quality of registered scan pairs.
If a scan failed at this QC stage (from here on referred to as DRC QC), it was
considered as failed for all BSI measures.
The BSI measures how much the boundary of a brain region has shifted
between successive scans using normalised voxel intensities of co-registered
images. Blurring due to patient motion can change the intensities of voxels
4.2. Materials and Methods 53




























MMSE score/30 29 (1) 28 (2) 28 (2) 23 (2)
Education, years 17 (3) 16 (3) 17 (2) 16 (3)
% female 54% 46% 46% 43%
% apolipoprotein (APOE) 4
carriers
31% 46% 61% 71%
Baseline to 6 months










MMSE score/30 29 (1) 28 (2) 28 (2) 23 (2)
Education, years 17 (3) 16 (3) 17 (2) 15 (3)
% female 50% 45% 48% 38%
% APOE 4 carriers 29% 42% 57% 77%
Baseline to 12 months










MMSE score/30 29 (1) 28 (2) 28 (2) 23 (2)
Education, years 17 (3) 16 (3) 17 (2) 15 (3)
% female 52% 44% 47% 27%
% APOE 4 carriers 27% 44% 56% 78%
Note: mean (sd) shown unless otherwise indicated
CN = cognitively normal, EMCI = early mild cognitive impairment, LCMI
= late mild cognitive impairment, AD = Alzheimer’s disease, MMSE = mini-
mental state examination (at baseline)
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at the brain boundary and may therefore render the BSI measure unreliable
[Preboske et al., 2006]. Since subjects had more opportunity to move during
the longer non-accelerated scan a strict quality control process was used (i.e.
erring on the side of excluding scans) as the first aim was to investigate whether
the image acquisition, rather than differences in motion, might influence BSI
measures. If motion, geometric distortions (due to different positioning in
the scanner) or significant quality differences between baseline and follow-up
scans were found, they were rated as unusable. In addition, any subjects whose
follow-up scans were performed on a different scanner from the baseline scans
were excluded.
4.2.3 Quality Comparison of accelerated and unaccelerated
scans
To evaluate quality the proportion of scan pairs that passed DRC QC was
examined. Patient motion is one of the major reasons a registered scan pair
may fail but other reasons, such as geometric distortions due to positional
differences may occur. It was hypothesised that there may be more motion
artefacts in non-accelerated scans than accelerated due to the longer time re-
quired for the non-accelerated scan, but that other reasons for failing QC such
as geometric distortions due to positional differences would be independent of
acquisition type. Therefore, in order to compare scan quality both the non-
accelerated and accelerated scan pair were excluded if either were failed for
reasons other than motion. Within the remaining scan pairs, a paired compar-
ison of the proportion of accelerated scan pairs that passed DRC QC and the
proportion of non-accelerated scan pairs that passed DRC QC was conducted
using the McNemar test [McNemar, 1947]. Where more than one scan was
acquired per session, the first scan to be acquired was used in this comparison
(in the BSI comparisons the best scan acquired was used).
4.2. Materials and Methods 55
4.2.4 Segmentation and volume measurement
Whole-brains were segmented using Multi-Atlas Propagation and Segmenta-
tion (MAPS) as described in chapter 3. They were visually checked and man-
ually edited if necessary (edits included removing skull inclusions, spillages
into non-brain tissue around the temporal lobes and cutting-off the brain stem
at the most inferior slice of the cerebellum). Differences in the numbers of
scans with brain, ventricle and hippocampal volumes available were due to
the work-flow at the Dementia Research Centre, whereby scans are released
for segmentation in batches and all regions are manually checked and edited
where necessary. This means that not all available scans had hippocampal
regions segmented and checked at the time of writing. All available scans were
included to maximise the numbers for the analyses.
4.2.5 Volume Change Measurement
Whole brain, ventricular and hippocampal volume change in 6- and 12- month
follow-up scans was calculated using the methods described in chapter 3.
4.2.6 Comparison of accelerated and unaccelerated volumes and
atrophy rates
Paired t-tests were used to compare baseline mean volumes and 6- and 12-
month atrophy rates between accelerated and unaccelerated scans. Differences
in variances were tested for using Pitman’s test for equality of variance in
paired samples.
To compare atrophy rates between accelerated and non-accelerated scan
pairs a family of linear mixed models developed for the analysis of repeated
measures of direct change [Frost et al., 2004] were used. Only scans that
passed DRC QC were included in this analysis. These models account for
the correlation between repeated atrophy measures and permit inclusion of all
available atrophy measures in the analysis under the assumption that missing
values are missing at random. The dependent variables in separate models
were the ml loss of brains, ventricles and hippocampi as calculated by the BSI
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(see equation below). Time (years) between baseline and follow-up scans was
included as a fixed-effect. Interactions terms between scan type and time were
included to allow atrophy rate to vary with scan type. Random effects for
visit were included to allow participants to have visit specific deviations from
a linear trajectory, and random effect for time allow for participant specific
differences from the mean rate of atrophy. The random effect of time was
allowed to differ by diagnostic group to allow for differing between subject
heterogeneity in atrophy rate. The model can be written as equation (1):
yi jk = (β0 +β1scantype+β2EMCI+β3LMCI+β4AD+bi,C +bi,EMCI
+bi,LMCI +bi,AD)ti jk−ui j +uik + εa,i jk + εna,i jk
bi,C ∼ N(0,σ2b,C),bi,EMCI ∼ N(0,σ2b,EMCI),
bi,LMCI ∼ N(0,σ2b,LMCI),bi,AD ∼ N(0,σ2b,AD)
ui j ∼ N(0,σ2u ),uik ∼ N(0,σ2u ),εa,i jk ∼ N(0,σ2a,ε),εna,i jk ∼ N(0,σ2na,ε)
Where yi jk is the measured change between the j-th and k-th visit for the
i-th individual, ti jk is the time interval between visits j and k, scantype is a cat-
egorical variable representing scan type (0 if accelerated, 1 if non-accelerated),
EMCI is a categorical variable representing EMCI status (0 if not diagnosed
as EMCI, 1 if diagnosis = EMCI) and likewise for LMCI and AD, β0 is the
mean atrophy rate in accelerated scans in controls, is the difference in mean
atrophy rate between accelerated and non-accelerated scans and are the fixed
effects coefficients corresponding to a diagnosis of EMCI, LMCI or AD, terms
are the random effect slope for subject i in the relevant diagnostic group and
εa,i jk and εna,i jk are the error terms for accelerated and non-accelerated scans
respectively. I hypothesised the residual error (εi jk ) may be differ between
non-accelerated scans and accelerated scans, as this represents the measure-
ment error introduced in making the direct BSI measurement of atrophy. It
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was assumed that all other variance components, such as between subject het-
erogeneity in their atrophy rates could not be plausibly influenced by the scan
type. Therefore, in order to test for differences in variance between accelerated
and non-accelerated scans the likelihood ratio test on nested models was used,
differing only in that one model specified with common residual variance (εi jk
) and one model had separate residual variances by scan type (εa,i jk ;εna,i jk ).
4.2.7 Comparison of subject characteristics between passed and
failed scans
Baseline mini-mental state exam (MMSE), age and vascular burden- white
matter hyperintensities (WMH) volumes (segmented on the Fluid-Attenuated
Inversion Recovery (FLAIR) scans at UC Davis using an automated tech-
nique) [DeCarli et al., 1999] were compared in subjects with scan pairs that
failed QC (where one or both of the 0-6 and 0-12 month scan pairs failed DRC
QC due to motion) with those who had only passing scan pairs (either 0-6
or 0-12 months or both if available) using linear regression. For the MMSE
score comparison age, gender, years of education and diagnosis were adjusted
for. For the WMH volume comparison age, baseline diagnosis and head size
were adjusted for. Since WMH volumes and MMSE scores are not normally
distributed bootstrapping (with 2000 iterations) was used to calculate bias-
corrected and accelerated 95% confidence intervals (confidence interval (CI))
for both of these analyses. For the age comparison baseline diagnosis was
adjusted for as the AD subjects were older than the EMCI subjects. The
proportion of subjects with cognitive impairment (EMCI, LMCI or AD) was
compared between the groups (failed vs non-failed scans) using logistic regres-
sion and calculated risk ratios.
4.2.8 Sample size estimates
Sample size requirements for a clinical trial to measure a 25% reduction in
whole-brain atrophy rates in accelerated and unaccelerated scans were esti-
mated using the standard formula: sample size per arm = (u + v)2× (σ12
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+ σ22 )/(µ1−µ2)2 , where u = 0.84 to provide 80% power and v = 1.96 to
test at the 5% level; µ and σ are the mean and SDs of rates of atrophy in the
treatment and placebo groups (assumes µ1 ≈ µ2). In order to directly com-
pare the sample size requirements using accelerated and unaccelerated scans,




The majority of scans failed by Mayo were failed due to non-adherence to the
ADNI protocol, incomplete coverage of the brain, metal induced artefacts or
pathology. Only one subject had scans failed by Mayo due to severe motion.
A total of 861 subjects had baseline accelerated and non-accelerated scans
available to download from LONI. Of these 840 subjects had both a baseline
accelerated and non-accelerated scan that passed DRC first pass QC. See Fig-
ure 4.1 for a detailed breakdown of the number of subjects at each stage of the
DRC QC.
Of the 576 subjects who had scans available at 6 months, scan pairs from
29 subjects were rated as unusable due to geometrical distortions due to po-
sitioning differences in the scanner being detected on either or both of the
accelerated and unaccelerated scans. A further 138 subjects had either an
accelerated or unaccelerated scan pair rated as unusable due to motion. Of
the 385 subjects who had scans available at 12 months, geometric distortion
was detected on either the accelerated or unaccelerated scan pairs or both
for 5 subjects and were therefore rated as unusable and a further 99 subjects
had either an accelerated or unaccelerated scan pair rated as unusable due to
motion.
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Figure 4.1: Breakdown of no. of subjects at each stage (NA = non-accelerated scan,
A = accelerated scan)
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4.3.2 Scan quality differences between accelerated and unaccel-
erated T1 MRI scans
At both 6- and 12- month intervals, significantly more (twice as many) un-
accelerated than accelerated scan pairs failed quality control due to motion
artefacts (in one or other of the pairs); at 6 months 14% of unaccelerated scan
pairs were failed due to motion vs 7% of accelerated scan pairs (p≤0.001);
at 12 months 20% of unaccelerated scan pairs failed due to motion vs 9% of
accelerated scan pairs (p≤0.001).
4.3.3 Baseline volumes
Table 4.2 summarises the mean baseline brain, ventricular and hippocampal
volumes measured from the baseline MRI scans. There were no differences in
the mean baseline brain or hippocampal volumes measured using accelerated
scans as compared with unaccelerated scans. The measured baseline ventricu-
lar volume was on average 0.09ml lower for unaccelerated compared to accel-
erated scans. Although this difference was statistically significant (p<0.001)
it was very small at only 0.2% of the mean ventricular volume. There were no
significant differences in variances of any of any of the measures.
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The results of the comparison of annualised brain, ventricular and hippocampal
atrophy rates calculated using the BSI from accelerated and non-accelerated
MRI scan pairs are shown in Table 4.3. No significant differences in whole-
brain, ventricular or hippocampal atrophy rates were found in any of the com-
parisons. Residual errors were generally slightly higher for non-accelerated
scans, although the difference only reached statistical significance in the hip-






Table 4.3: Comparison of whole-brain ventricular and hippocampal atrophy rates calculated from accelerated and non-accelerated scan
pairs using the boundary shift integral in subjects whose accelerated and non-accelerated scan pairs both passed QC, mean (se)
























All 487 5.81 (0.88) 5.85 (0.88)
0.04 [-0.28 to 0.36],
p=0.802
5.41 (0.57) 6.66 (0.60) p=0.153
GE 91 6.52 (1.99) 7.12 (2.01)
0.60 [-0.65 to 1.86],
p=0.347
12.71 (2.68) 19.16 (3.53) p=0.153
Siemens 289 6.44 (1.23) 6.44 (1.23)
0.00 [-0.36 to 0.36],
p=0.986
0.48 (0.90) 1.11 (0.95) p=0.358
Philips 107 4.61 (1.99) 4.31 (1.99)
-0.30 [-0.72 to 0.13],
p=0.168
2.25 (0.58) 2.91 (0.60) p=0.506
Ventricles
All 487 1.30 (0.22) 1.30 (0.22)
0.01 [-0.02 to 0.03],
p=0.619
0.01 (0.01) 0.01 (0.01) p=0.589
GE 91 0.86 (0.52) 0.92 (0.52)
0.06 [-0.03 to 0.15],
p=0.225
0.01 (0.03) 0.04 (0.03) p=0.483
Siemens 289 1.57 (0.27) 1.57 (0.27)
0.00 [-0.03 to 0.03],
p=0.998
0.001 (0.005) 0.01 (0.01) p=0.450
Philips 107 0.92 (0.53) 0.91 (0.53)
-0.01 [-0.07 to 0.04],
p=0.647
0.02 (0.01) 0.00 (0.01) p=0.492
Hippocampi
All 227 0.05 (0.02) 0.04 (0.02)
-0.01 [-0.02 to 0.00],
p=0.262
0.004 (0.000) 0.004 (0.0005) p=0.795
GE 45 -0.06 (0.09) -0.08 (0.09)
-0.02 [-0.05 to 0.00],
p=0.100
0.003 (0.002) 0.002 (0.002) p=0.347
Siemens 126 0.07 (0.01) 0.06 (0.01)
-0.01 [-0.02 to 0.00],
p=0.125
0.001 (0.001) 0.002 (0.001) p=0.381
Philips 56 0.03 (0.02) 0.04 (0.02)
0.01 [-0.00 to 0.03],
p=0.121
0.002 (0.000) 0.003 (0.001) p=0.045
* results are from the model with two separate residual errors by scan type
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4.3.5 Comparison of subject characteristics between those with
failed scan pairs due to motion and those with passed scan
pairs
Unadjusted baseline WMH volumes, age, MMSE scores and change in MMSE
over 12 months along with the results of the regression analyses comparing
these variables in subjects who had one or more scan pairs that failed DRC
QC due to motion with those whose scan pairs passed DRC QC are shown in
table 4.4.
4.3.5.1 In accelerated scan pairs
Subjects who had a failed 0-6 or 0-12 month accelerated scan pair (due to
motion) had a lower mean adjusted WMH volume (adjusted for age, diagnosis
and head-size) and had a higher mean adjusted age (adjusted for diagnosis).
There was no significant association between the proportion of cognitively
impaired subjects and QC failure due to motion, nor was an association found
between baseline MMSE score and QC scan pair failure.
4.3.5.2 In unaccelerated scan pairs
A higher proportion (11% higher) of subjects who had a failed 0-6 or 0-12
month unaccelerated scan pair (due to motion) were cognitively impaired com-
pared with those whose scan pairs passed QC (p=0.01). Subjects who had a
failed 0-6 or 0-12 month unaccelerated scan pair (due to motion) also had a
lower mean adjusted MMSE score (adjusted for age, gender, education and
diagnosis) (p ≤ 0.05). No significant difference in WMH volumes or age was
found.
4.3.6 Sample size estimates
Mean annualised brain atrophy rates by diagnostic group are shown in Table
4.5 and estimated sample sizes for subjects with LMCI and AD are shown in
Table 4.6. No significant differences in sample size requirements were found
when comparing accelerated and unaccelerated scan pairs for any of the atro-
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phy measures.
Table 4.4: Comparison of subject characteristics between those with failed scan pairs
due to motion and those with passed scan pairs
Both (if available)
0-6 and 0-12 month
scan pairs passed
QC
One or both of the
0-6 and 0-12 month








6.55 (8.96), n=498 9.40 (9.71), n=66
2.01a [0.01, 4.62],
p≤0.05
Age (years) 72.2 (7.4), n=513 74.3 (6.7), n=66
2.2b [0.4, 4.0],
p=0.02













6.85 (9.28), n=444 7.01 (8.40), n=120
-0.32a [-1.82,
1.49], p>0.05
Age (years) 72.3 (7.2), n=455 72.9 (7.6), n=124
0.9b [-0.6, 2.3],
p=0.24









a Difference in mean WMH volume adjusted for age, diagnosis and headsize using linear re-
gression analysis. CI calculated using bootstrapping. b Difference in baseline age adjusted
for diagnosis using linear regression analysis c Difference in baseline MMSE score adjusted






Table 4.5: Atrophy rates by diagnosis in all subjects (regardless of whether scan pairs passed or failed QC)











Annualised whole-brain atrophy rates ml/year
CN 157 7.21 (14.65) 6.74 (13.71) 122 7.18 (7.7) 7.37 (7.48)
EMCI 234 7.44 (13.89) 7.52 (14.15) 122 7.82 (8.92) 7.5 (8.35)
LMCI 129 11.48 (15.01) 11.16 (14.25) 103 10.84 (9.68) 11.01 (9.18)
AD 52 16 (15.97) 16.06 (15.06) 37 14.89 (8.24) 14.94 (9.2)
Annualised ventricular expansion rates ml/year
CN 157 1.31 (2.45) 1.42 (2.59) 122 1.43 (1.54) 1.41 (1.52)
EMCI 234 1.4 (2.47) 1.39 (2.51) 122 1.77 (1.81) 1.76 (1.79)
LMCI 129 2.7 (3.17) 2.7 (3.09) 103 2.94 (2.59) 2.91 (2.59)
AD 52 4.2 (4.21) 4.39 (4.17) 37 4.14 (3.01) 4.16 (2.95)
Annualised hippocampal atrophy rates ml/year
CN 115 0.08 (0.22) 0.08 (0.22) 92 0.06 (0.11) 0.07 (0.11)
EMCI 180 0.06 (0.17) 0.07 (0.17) 85 0.09 (0.14) 0.1 (0.14)
LMCI 95 0.15 (0.23) 0.14 (0.22) 76 0.13 (0.15) 0.14 (0.14)
AD 38 0.2 (0.16) 0.21 (0.21) 25 0.18 (0.12) 0.18 (0.11)
Note: mean (sd) shown unless otherwise indicated
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Table 4.6: Sample size estimates for a 25% reduction in atrophy rate (with bootstrap













Baseline to 6 months
LMCI Brains 420 [257, 858] 414 [258, 759] 6 [-100, 146]
LMCI Ventricles 349 [241, 692] 334 [226, 633] 15 [-38, 50]
LMCI Hippocampi 673 [342, 1851] 612 [340, 1707] 61 [-226, 763]
AD Brains 252 [146, 606] 223 [127, 529] 29 [-65, 248]
AD Ventricles 254 [160, 466] 228 [145, 427] 26 [-3, 75]
AD Hippocampi 145 [89, 270] 236 [136, 576] -91 [-153, 19]
Baseline to 12 months
LMCI Brains 204 [139, 371] 177 [127, 277] 27 [-14, 76]
LMCI Ventricles 202 [148, 320] 205 [149, 329] -3 [-16, 10]
LMCI Hippocampi 361 [221, 853] 234 [160, 415] 127 [-16, 435]
AD Brains 77 [53, 126] 96 [56, 203] -19 [-47, 23]
AD Ventricles 134 [89, 244] 127 [85, 232] 7 [-1, 20]
AD Hippocampi 110 [58, 328] 93 [40, 621] 17 [-64, 172]
4.4 Discussion
A significantly lower proportion of accelerated scan pairs than unaccelerated
were found to suffer from poorer quality due to motion artefacts. Further
whole-brain, ventricular and hippocampal volumes and atrophy rates calcu-
lated from accelerated MRI scans were shown to be comparable to those cal-
culated from unaccelerated MRI scan pairs in a large cohort of control, MCI
and AD subjects. Differences were also found in the characteristics of those
who failed the accelerated and unaccelerated scan pairs: those who had failed
unaccelerated scan pairs had a lower MMSEs at baseline (more severe) and
a higher proportion of them were cognitively impaired whereas those whose
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accelerated scan pairs failed DRC QC were older and had greater WMH vol-
umes. The difference in WMH volumes remained even after adjustment for
age suggesting that subjects with more extensive white matter damage are
less able to remain sufficiently motionless even at the shorter scanning times.
Therefore, disregarding data from subjects with unusable scans due to motion
changes the characteristics of the participants included in any analysis, mean-
ing that they may have different characteristics from those who were originally
recruited to the study.
One previous study investigated the influence of parallel imaging acqui-
sition on brain volume measurements in 4 healthy control subjects [Krueger
et al., 2012]. They acquired 12 Magnetization Prepared RApid Gradient Echo
(MPRAGE) volumes in each session with a range of acceleration factors. They
then repeated the same sequences 8 weeks later in each of the 4 subjects and
found no significant differences in BSI measures even at high acceleration fac-
tors.
A further two previous studies investigated the influence of using acceler-
ated T1 acquisitions on different measures of brain atrophy rate [Ching et al.,
2015, Vemuri et al., 2015]. Both of these studies used data from ADNI. One
study found that measures of atrophy rate derived from tensor based mor-
phometry were very similar between accelerated and unaccelerated acquisi-
tions [Ching et al., 2015]. Another study [Vemuri et al., 2015], which used a
different atrophy rate measure based on symmetric diffeomorphic image nor-
malisation and tensor based morphometry (TBM-Syn), did find some signifi-
cant differences, with accelerated scan pairs tending to show higher TBM-Syn
scores (or lower rates of atrophy) compared with unaccelerated pairs.
There are some limitations to this study. First, subjects always had the
unaccelerated scan prior to the accelerated scan. It could be that the finding
of more motion artefacts in the unaccelerated scans was due to the ordering
of the scans rather than the longer scan time. Secondly, the motion artefacts
were visually rated and the rater was not blinded to the type of scan per-
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formed, which may have introduced some bias. Thirdly, although the results
of this study indicate that atrophy rates measured using the BSI in acceler-
ated scans are not markedly different from those measured in unaccelerated
scans, it may be that different techniques for measuring brain atrophy rates are
more susceptible to the changes in scan characteristics introduced by parallel
imaging techniques. Notably, a small, but statistically significant difference in
hippocampal atrophy rates between accelerated and unaccelerated scan pairs
at 12 months was found. The signal-to-noise ratio (SNR) ratios in accelerated
scans are highest near the head coils, on the surface of the brain and get pro-
gressively worse, as the distance from the coils increases [Krueger et al., 2012].
The hippocampal BSI may therefore be more sensitive to the differences in
accelerated and unaccelerated scans due to their location deep in the brain. It
may be that with longer time intervals, these differences become more apparent
and further studies would be required to investigate this.
In summary, the shorter scan time of accelerated scans may reduce the
proportion of scans rendered unusable due to motion artefacts. Importantly,
the use of accelerated T1 structural MRI scans in place of unaccelerated scans
does not appear to have an impact on whole-brain, ventricular and hippocam-
pal volume and atrophy rate (BSI) measures. Therefore it may be advanta-
geous to use accelerated T1 MRI scans rather than unaccelerated scans for
assessing brain volumes and atrophy rates (BSI) in clinical trials. In addition,
the use of accelerated T1 instead of unaccelerated would permit more time to
be devoted to other imaging types without having a negative impact on the
derived metrics. Finally, differences in subject characteristics were observed in
those subjects whose scan pairs passed DRC QC from those whose scan pairs
failed DRC QC due to motion in both accelerated and unaccelerated scans.
Disregarding data from subjects who are unable to keep sufficiently still dur-
ing an MRI scan to produce quality data ultimately biases the characteristics
of the subject group in some way, possibly excluding those subjects who are
more severe or have a more vascular form of the disease. However, the use
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of accelerated T1 volumetric scans rather than unaccelerated T1 volumetric
scans means that higher quality longitudinal image can be obtained on a larger
proportion of the original study population.
Chapter 5
Investigation into hippocampal atrophy
in apolipoprotein (APOE) ε4 carriers
5.1 Introduction
Hippocampal atrophy rate has been proposed as an imaging biomarker for
Alzheimer’s disease (AD) progression [Barnes et al., 2004, van der Flier and
Scheltens, 2009]. However, it is essential to understand how factors might affect
hippocampal atrophy rates if this biomarker is to be used most effectively in
clinical trials.
Numerous publications have attempted to elucidate whether APOE mod-
ifies hippocampal atrophy rates [Chiang et al., 2011,Cohen et al., 2001,Crivello
et al., 2010,Hashimoto et al., 2009,Jack et al., 1998,Lo et al., 2011,Moffat et al.,
2000, Mori et al., 2002, Morra et al., 2009, Risacher et al., 2010, Schuff et al.,
2009,Spampinato et al., 2011,Van De Pol et al., 2007,Wang et al., 2009,Wolz
et al., 2010]. Although some studies reported elevated hippocampal atrophy
rates in ε4+ in AD, mild cognitive impairment (mild cognitive impairment
(MCI)) and control groups, it is possible that the greater hippocampal rates
observed could have been attributed to higher concurrent whole-brain atrophy
rates and therefore faster disease progression.
To better understand the effect of the APOE ε4 allele on the progression
of structural brain changes the aim of this study was to investigate whether
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different whole-brain and hippocampal atrophy rates were observed in ε4+
compared with ε4- in AD, MCI and controls. Further, to investigate if there
is evidence of higher hippocampal atrophy rates in ε4+ when adjusting for
concurrent whole-brain atrophy rates, which has not been examined previously.
5.2 Methods
5.2.1 Subjects
Subjects from Alzheimer’s disease neuroimaging initiative (ADNI)-1 who had
a baseline magnetic resonance imaging (MRI) scan and at least 1 follow-up
scan were included in this study. Details of the ADNI cohort are given in
3.1.1. Each subject underwent APOE genotyping at the screening visit. All
demographic information, diagnoses, neuropsychological test scores and APOE
genotype data were downloaded from the ADNI clinical data repository.
Since a proportion of MCI subjects will likely not progress to dementia
caused by AD, this group is likely to be quite heterogeneous with respect to
underlying pathology. As a result, the MCI subjects were dichotomised into
those who were observed to progress to a clinical diagnosis of AD within 36
months of baseline and maintained that diagnosis (MCI-P) and those who were
stable over the follow-up period (MCI-S). Subjects whose diagnosis changed
from MCI to AD and subsequently reverted to MCI during the study were
excluded as were subjects whose diagnosis changed from MCI to normal. ε2
carriers (i.e. ε2/ε2, ε2/ε3 and ε2/ε4 subjects) were also excluded from the
study as they may have lower hippocampal atrophy rates [Chiang et al., 2010].
There were a total of 840 ADNI-1 subjects available at the time of this study,
after exclusions this number reduced to 622 subjects. The number of subjects
excluded at each exclusion stage is summarised in Figure 5.1.
5.2.2 Image acquisition and analysis
The ADNI-1 MRI protocol used in this study is described in 3.2.1.1. Those
scans with significant motion artefacts were excluded from the current
study. Whole-brain and hippocampi were automatically delineated using the
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Figure 5.1: Subject selection process
Multi-Atlas Propagation and Segmentation (MAPS) technique from the pre-
processed 1.5-T T1-weighted MRI scans at all available time-points [Leung
et al., 2010a, Leung et al., 2011]. For details on the MAPS method used see
3.4.1 and 3.4.3.1. The change in the volumes of the whole-brain and hip-
pocampi between follow-up and baseline were calculated using the methods
described in chapter 3. Total intra-cranial volume (total intracranial volume
(TIV)) was estimated by summing the volumes of grey matter, white mat-
ter, and cerebrospinal fluid (cerebrospinal fluid (CSF)) segmentations using
SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8). Brain-to-TIV ratio




APOE ε4 carrier status was coded as 1 for carriers of 1 or 2 ε4 alleles and
0 for those who did not carry an ε4 allele. The effect of APOE ε4 carrier-
status on the volume of the sum of the left and right hippocampi at baseline
adjusting for the level of overall whole-brain atrophy was investigated. To do
this a linear regression was performed within each clinical group with bilateral
hippocampal volume as the dependent variable and APOE ε4 carrier-status,
age, gender, mini-mental state exam (MMSE) score, TIV and brain-to-TIV
ratio included as covariates. Age was included as a covariate as normal aging
is associated with brain volume loss, TIV to control for variation in head size
and gender to control for any differences in male-to-female ratio between the
different genotype groups. MMSE score and brain-to-TIV ratio were included
as covariates in order to assess the effect of the APOE ε4 carrier-status above
and beyond any global differences in cognitive impairment and whole-brain
atrophy.
To analyse the effect of the APOE ε4 carrier-status on the rate of atro-
phy of the hippocampi and whole-brain (as measured using the boundary shift
integral (BSI)), joint linear mixed models were used. These models allow the
random-effects dictating the trajectories of hippocampal and whole-brain at-
rophy to be correlated, thus permitting estimates of hippocampal atrophy rate
adjusted for true whole-brain atrophy rate. They allow for repeated measures
and accommodate missing values under the missing at random assumption.
The dependent variables were the ml loss of hippocampi as calculated by the
hippocampal-BSI and brain as calculated by the brain-BSI.
Interval (years) between baseline and follow-up scans was included as a
fixed-effect and interactions terms between APOE ε4 carrier-status and scan
interval were included to allow hippocampal atrophy rate to vary with APOE
ε4 carrier-status. Interactions of interval with age, MMSE score, brain-to-TIV
ratio, gender and TIV (all measured at baseline) were also included as fixed-
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effects in the model. Interval was also included as a random-effect, to allow
for between subject heterogeneity in atrophy rate. No constant terms (fixed or
random) were included, consistent with the assumption that true (as opposed
to measured) atrophy between two scans from the same time-point is zero.
A single joint model was fitted to both hippocampal and whole brain losses,
allowing distinct fixed and random effect parameters for the two processes.
The two trajectories were linked through a correlation between the two random
slopes. The difference in mean hippocampal rates between ε4+ and ε4- after
adjustment for concurrent brain atrophy rate was then estimated. This was
calculated as the difference in hippocampal rates (unadjusted for brain atrophy
rate), minus the difference attributable due to differences in brain rates (based
on the standard deviations of the random-slopes and their correlation in the
joint model). See the appendix for the expressions of the statistical models
used.
Since gender was included as a binary categorical variable in the analyses
the mean adjusted values for a 50/50 split of males: females is presented in
the Figures and Tables (adjusted for disease-group specific mean age, baseline
brain-to-total intracranial volume ratio, MMSE score and total intracranial
volume). The mean adjusted values for a 50/50 gender split were calculated
by multiplying the coefficients for males and females by 0.5 and adding them
together. Given that an interaction term between ε4 carrier-status and gender
was not included in the analyses, the differences in whole-brain and hippocam-
pal atrophy rates are the same for males and females.
5.3 Results
Table 1 shows demographics and imaging summary statistics for each clinical
group used in this study. As previously shown [Leung et al., 2010b], the AD
subjects had smaller mean hippocampal volumes at baseline than MCI subjects
whose hippocampi were in turn smaller than control subjects (Table 5.1); the
mean hippocampal volume for the AD subjects was 20% smaller than the
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Table 5.1: Baseline demographics and image summary statistics by clinical group.







No. Subjects (at 6m, at 12m, at













No. ε4 non-carriers (% total),
No. ε4 heterozygotes (% total),













% male 54% 66% 59% 55%
Age [years] 76.0 (5.1) 75.5 (7.2) 74.2 (6.9) 75.0 (7.6)
MMSE score 29.2 (0.9) 27.2 (1.8) 26.6 (1.7) 23.4 (1.9)




5.2 (0.7) 4.6 (0.8) 4.2 (0.8) 3.9 (0.9)
controls with the MCI-P and MCI-S subjects having intermediate volumes.
5.3.1 Baseline cross-sectional results
Table 2 and Figure 5.2 show the results of the cross-sectional analysis of hip-
pocampal volumes. In AD, after adjustment for age, gender, MMSE score,
brain-to-TIV ratio and TIV, the mean baseline hippocampal volume of ε4+
was significantly smaller than that of ε4- (by 8%). There was no evidence of a
difference in mean adjusted baseline hippocampal volume between ε4 carriers
and non-carriers in MCI-P, MCI-S or controls.
5.3.2 Longitudinal Results
Table 3 and Figure 5.3, Figure 5.4 and Figure 5.5 show the results of the
longitudinal analyses of the differences in mean adjusted atrophy rates between
ε4+ and ε4- in all subject groups.
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Table 5.2: Adjusted mean baseline hippocampal volumes for ε4 non-carriers and
adjusted mean differences in total (left and right summed) baseline hip-
pocampal volumes between ε4 carriers and non-carriers in controls, stable









































* all values are for a 50/50 gender split and are adjusted for disease-group specific mean age,
baseline brain-to-total intracranial volume ratio, MMSE score, and total intracranial volume
** average of left and right






Table 5.3: Adjusted mean difference in whole-brain and hippocampal atrophy rate (ml) [95% CI] for ε4 carriers compared with non-carriers
in controls, stable MCI, MCI progressors and AD (+ve means atrophy rate is higher in ε4+).
ε4 carrier status Controls (ε4-
=118, ε4+ =49)
MCI stable (ε4-
= 86, ε4+ = 83)
MCI progressors






Mean adjusted* atrophy rate
(ml/year)




Difference in mean adjusted*
atrophy rate (ml/year)




















Difference in mean adjusted*
atrophy rate (ml/year)








Difference in mean adjusted*
atrophy rate after adjustment for
concurrent whole-brain atrophy
rate (ml/year)








* all values are for a 50/50 gender split and are adjusted for disease-group specific mean age, baseline brain-to-total intracranial volume ratio, MMSE
score, and total intracranial volume ** average of left and right
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There was statistically significant evidence that in AD, MCI-P and MCI-S
subjects, after adjusting for age, gender, TIV, MMSE score and brain-to-TIV
ratio, the mean hippocampal atrophy rates were higher in ε4+ compared with
ε4- (see Figure 5.3). Mean adjusted brain atrophy rates were also higher in ε4+
compared with ε4-, but only significantly so in the MCI-S group (see Figure
5.4). After adjustment for concurrent whole-brain atrophy, the difference in
atrophy rate between ε4+ and ε4-was reduced by 25% in AD, by 40%
in MCI-P and by 75% in MCI-S (see Figure 5.5). Although the differences
in mean adjusted hippocampal atrophy rates were reduced when additionally
adjusting for concurrent whole-brain loss, differences between ε4+ and ε4-
remained statistically significant in AD and MCI-P. In the control group there
was no evidence that hippocampal or whole-brain atrophy rate differed between
ε4+ and ε4- (p>0.8 for both).
5.4 Discussion
This study examined the effect of APOE genotype on hippocampal volumes
and hippocampal atrophy rates in AD, MCI and in controls, with and without
adjusting for concurrent brain atrophy rates.
Cross-sectionally it was found that AD ε4+ had smaller ( 8%) mean hip-
pocampal volumes at baseline than ε4- after adjusting for age, TIV, gender,
MMSE score and brain-to-TIV ratio. There was no evidence that ε4+ had
smaller hippocampal volumes than non-carriers in MCI-P, MCI-S or controls.
Longitudinally, mean adjusted hippocampal atrophy rates were found to
be higher in ε4+ in AD, MCI-P and MCI-S but not in controls. There was also
evidence that mean adjusted hippocampal atrophy rates were higher in ε4+ in
AD and MCI-P after adjusting for concurrent whole-brain atrophy rates. The
difference in hippocampal atrophy rates in MCI-S was no longer significant
after adjustment for concurrent brain atrophy rate.
Taken together these results demonstrate that ε4 carriers with a clinical
diagnosis of AD or of progressive MCI have a different pattern of atrophy - dis-
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Figure 5.3: Effect of APOE ε4 on hippocampal atrophy rates.*
proportionately greater hippocampal loss - than non-carriers. Cross-sectional
studies have shown reduced hippocampal volumes in ε4+ compared with ε4-
in AD. However, without investigating longitudinal changes in hippocampal
volume, it is not possible to tell whether these findings could be perhaps ex-
plained by developmental differences. Indeed, there is evidence that there are
some developmental differences with one study reporting higher Mental De-
velopment Index scores in 24 month old babies who were ε4+ compared with
those who were ε4- [Wright et al., 2003]. There are few studies in healthy
young people comparing hippocampal volumes in ε4+ and ε4-. One study in
a large cohort of adolescents reported no significant difference in hippocampal
volumes between ε4+ and ε4- [Khan et al., 2013] whilst another smaller study
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Figure 5.4: Effect of APOE ε4 on whole-brain atrophy rates
Effect of APOE ε4 on whole-brain atrophy rates.*
in young adults reported significantly smaller hippocampi in ε4+ [O’Dwyer
et al., 2012]. However, the study in adolescents did not adjust for head size
whilst the study in young adults did, which makes comparisons between the
studies difficult. Further studies would be required to understand the devel-
opmental differences between ε4+ and ε4-.
In older adults previous longitudinal studies have reported higher hip-
pocampal rates in ε4+ compared with ε4-. However, higher rates of hip-
pocampal atrophy in ε4+ could be potentially explained by higher rates of
whole-brain atrophy (i.e. a more aggressive disease course with a more rapid
loss of whole-brain tissue). In order to disentangle the effects of the ε4 allele
on global and local hippocampal atrophy it is necessary to adjust hippocampal
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Figure 5.5: Difference in hippocampal atrophy rates*: ε4+ vs ε4-.
atrophy rates for global atrophy rates (whole-brain). In this study it was found
that hippocampal atrophy rates were still higher in ε4+ in AD and progres-
sive MCI following adjustment for whole-brain atrophy rates. This suggests
that higher hippocampal atrophy rates found in ε4+ are unlikely to be simply
due to a more aggressive disease with faster disease progression (as measured
by generalised brain tissue loss) alone. It may be that AD associated with
the ε4 allele is a different anatomical disease to AD without this allele, which
should be considered when assessing the effect of potentially disease modifying
treatments.
The finding of a lack of substantive differences between ε4+ and ε4- in
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hippocampal volume and atrophy rate in healthy control subjects is in agree-
ment with some previous findings [Jack et al., 1998, Lo et al., 2011, Schuff
et al., 2009,Wang et al., 2009]. Conversely, a number of previous studies have
reported increased hippocampal atrophy rates for ε4+ compared with ε4- con-
trols [Chiang et al., 2011,Cohen et al., 2001,Crivello et al., 2010,Moffat et al.,
2000, Morra et al., 2009, Risacher et al., 2010, Wolz et al., 2010, Jak et al.,
2007,Lu et al., 2011]. However, inconsistencies in findings between this study
and that of some of the others may be due to different recruitment strate-
gies: some studies had less stringent inclusion criteria than ADNI by including
some MCI subjects with controls [Moffat et al., 2000, Jak et al., 2007]; some
had a majority of subjects with a 1st degree relative with a history of AD [Co-
hen et al., 2001]. Differences in study design may also explain inconsistencies:
some studies measured atrophy over a longer period, thus increasing the power
with which to estimate differences in atrophy rates [Crivello et al., 2010,Moffat
et al., 2000, Lu et al., 2011]. In the largest longitudinal study to date, with
over 200 ε4 heterozygotes, no evidence of a difference in rates between het-
erozygotes and non-carriers was found [Crivello et al., 2010], consistent with
the findings of this study.
Interestingly, different studies using subsets of the controls in the ADNI
cohort have reported conflicting findings. Some reported significant evidence
of an association between APOE genotype and bilateral hippocampal atrophy
rate [Chiang et al., 2011, Risacher et al., 2010]. One study that analysed the
left and right sides separately reported a significantly higher rate of hippocam-
pal atrophy on the right side hippocampus in ε4+ compared with ε4- [Wolz
et al., 2010] another reported a significantly higher atrophy rate in the left
hippocampi in ε4+ compared to ε4- [Morra et al., 2009]. Others found no
such association [Lo et al., 2011,Schuff et al., 2009]. Differences between find-
ings of these studies and this study may be due to inclusion of ε2 carriers in
most studies since ε2 carriers have shown lower hippocampal atrophy rates
compared with non-carriers [Chiang et al., 2010].
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Reported results in MCI subjects are also mixed; a number of publications
have shown a significantly greater hippocampal atrophy rate in ε4+ compared
with ε4- [Chiang et al., 2011, Lo et al., 2011, Spampinato et al., 2011, Wolz
et al., 2010]. One study reported a significantly greater atrophy rate in the
left hippocampus [Morra et al., 2009]. Conversely other studies reported no
significant difference between ε4+ and ε4- in hippocampal atrophy rate in
MCI [Schuff et al., 2009,Wang et al., 2009].
In the majority of the studies using data from ADNI an association has
been found between ε4 carrier-status and higher hippocampal atrophy rates
in MCI much like this study. This is unsurprising in many ways since the
MCI group has a high proportion of subjects who will progress to clinical AD;
these subjects are more likely to be ε4+ and more likely to have increased hip-
pocampal atrophy when compared with the MCI subjects who remain stable
and may be less likely to have underlying AD pathology and less likely to be
an ε4 carrier.
Other studies have examined hippocampal atrophy rates in MCI-S and
MCI-P separately. One study, using voxel based morphometry (VBM) found
increased hippocampal atrophy rates in MCI-P ε4+ compared with ε4- but not
in MCI-S [Spampinato et al., 2011]. Another study, which used a number of
hippocampal measures, found significantly higher rates in ε4+ in all measures
in the MCI stable group [Risacher et al., 2010]. In MCI-P they only found
significantly increased loss of hippocampal grey matter (grey matter (GM))
density and GM volume in ε4+ but not hippocampal volume (as measured
by FreeSurfer). No evidence of a difference in hippocampal atrophy rates in
the MCI-S group after adjusting for concurrent whole-brain atrophy rate was
found.
The finding in this study in AD of smaller hippocampi in ε4+ at baseline
compared with ε4- is in keeping with a previous study which reported evi-
dence of a negative association between ε4 dose and normalised hippocampal
volume in AD subjects when adjusting for other covariates such as MMSE
5.4. Discussion 84
score [Hashimoto et al., 2009]. Further, the longitudinal findings in this study
in AD of increased hippocampal atrophy rates in ε4+ compared with ε4- are in
line with some previous studies [Lo et al., 2011,Mori et al., 2002,Schuff et al.,
2009]. Other studies report mixed or negative results for this comparison which
may depend on the image analysis methodology: one study reported increased
hippocampal GM atrophy in ε4+ but no significant increase in hippocampal
atrophy (as measured with FreeSurfer) or GM density changes [Risacher et al.,
2010]; Others found no significant difference in hippocampal loss rates between
ε4+ and ε4- in AD [Chiang et al., 2011,Morra et al., 2009].
A strength of this study was the relatively large number of subjects with
data from multiple time-points (up to 36 months from baseline). ADNI has the
advantage of being a prospective study with standardised follow-up times and
high quality MRI imaging. The MAPS hippocampal segmentation technique
was used which has been shown to have good accuracy when compared with
manual segmentations [Leung et al., 2010b]. In addition, the analysis method
has the advantage of a robust and direct longitudinal measure of hippocampal
and whole brain change, the BSI.
This study also has a number of limitations. Much like in the previous
chapter, the ADNI clinical diagnoses have not been pathologically confirmed
and it may be that some AD diagnoses will prove to be caused by non-AD
pathology at autopsy. Secondly, since the segmentation method used in this
study (hippocampal-MAPS) excludes the hippocampal tail, and it is possible
that atrophy rates differ across hippocampal sub-regions, early changes in con-
trol subjects positive for the ε4 allele could potentially have been missed and
including this region in all subject groups may change the results. Thirdly,
the longitudinal model assumes that the missing observations were missing at
random, an assumption which cannot be empirically verified. Finally, subjects
with an ε2 allele were excluded in order not to confound the results. It would
be of particular interest to investigate hippocampal atrophy rates in ε2/ε4
subjects as compared with other genotypes to evaluate whether ε2 or ε4 has
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greater influence on rates; however this genotype was rare in this dataset (only
3 controls, 2 MCI-S, 5 MCI-P and 2 ADs had the ε2/ε4 genotype).
In summary, the association of hippocampal volume and hippocampal at-
rophy rate with APOE genotype was investigated, while adjusting for age,
gender, cognitive impairment (MMSE score), baseline atrophy level (brain-to-
TIV ratio) and for head size in the case of cross-sectional analysis and longitu-
dinal analysis modelling atrophy in terms of absolute volume loss. There was
evidence that within the AD group ε4+ had lower mean adjusted hippocam-
pal volumes at baseline compared with ε4-. AD, MCI-P and MCI-S ε4+
had higher mean adjusted hippocampal atrophy rates compared with ε4- and
furthermore AD and MCI-P ε4 carriers still showed higher mean adjusted hip-
pocampal atrophy rates after adjustment for concurrent whole-brain atrophy
rates (which, to my knowledge, has not be previously shown). Higher atrophy
rates in ε4+ suggest that the patterns of atrophy are not merely manifesta-
tions of developmental differences according to genotype. These results thus
support the hypothesis that in AD the ε4 allele influences disease phenotype
with greater hippocampal involvement compared with non-carriers.
Chapter 6
Investigation into hippocampal shape
and volume in Posterior Cortical
Atrophy
6.1 Introduction
The hippocampus, known to play an important role in the formation of long-
term, consciously accessible memories [Mayes et al., 2007,Squire et al., 2007],
is one of the earliest structures to atrophy in typical Alzheimer’s disease
(tAD). Recently, hippocampal atrophy, visually or volumetrically assessed us-
ing magnetic resonance imaging, has been included in diagnostic criteria for
Alzheimer’s disease (AD) [Dubois et al., 2007, Hyman et al., 2012]. In addi-
tion, lower hippocampal volumes have been proposed as an enrichment strat-
egy to select individuals at risk of developing clinical AD for trials of putative
treatments [Hill et al., 2014]. Hippocampal atrophy has not been extensively
studied in posterior cortical atrophy (PCA); one previous study reported re-
duced grey matter volume in the right hippocampus (but not left) in PCA
as compared with controls using voxel-based morphometry [Whitwell et al.,
2007]. Evaluating the extent to which the hippocampus is affected in PCA
may contribute to efforts to improve our understanding of the factors driv-
ing phenotypic heterogeneity in AD. More practically, the value of biomarkers
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such as hippocampal atrophy may also differ in PCA compared with typical
Alzheimer’s disease, and have a bearing upon the question of whether to in-
clude individuals with PCA in clinical trials in which study outcome measures
have been selected for patients with more typical amnestic or global clinical
presentations [Crutch et al., 2012]. In this study, the aims were to: investigate
hippocampal volume differences between PCA, tAD and healthy controls; lo-
calise areas of hippocampal tissue loss; and investigate whether shape metrics
give any additional group separation information above volume alone.
6.2 Methods
6.2.1 Subjects
This study included data from 124 subjects who were identified retrospectively
from a clinical database at the Dementia Research Centre (PCA (n=47), typ-
ical AD (tAD; n=29), and control subjects (n=48)). The subjects included in
this chapter are described in detail in 3.1.4.
6.2.2 Image acquisition
The magnetic resonance imaging (MRI) acquisition protocols used in this chap-
ter are described in detail in 3.2.4.
6.2.3 Image processing
In-house segmentation software [Freeborough et al., 1997] was used to segment
whole-brains and hippocampi.
Whole-brain regions were segmented in native space using a semi-
automated technique [Freeborough et al., 1997] and were manually edited
where necessary. These whole brain regions were used to generate a volume,
and also to use in the subsequent registration step.
The MRI scans were then aligned to Montreal Neurological Institute
(MNI) space and resampled to produce isotropic voxels of 1 mm x 1 mm x 1
mm. The left and right hippocampi were manually segmented by experienced
image analysts. The hippocampi were manually delineated (by other image
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analysts) using every coronal slice referencing a standard neuroanatomical at-
las [Duvernoy, 2005] using a protocol that was largely similar to the EADC-
ADNI Harmonized Hippocampal Protocol (HarP) [Boccardi et al., 2015a]. The
protocol used in this study includes the head, body and full extent of the hip-
pocampal tail. Two key differences between our protocol and HarP were 1)
The white matter that separates the lateral ventricles from the grey matter
of the hippocampus at the level of the hippocampal tail was excluded and 2)
vertical digitations were excluded from the hippocampal head. In addition, a
minimum threshold of 70% of the mean whole brain intensity (using the whole
brain region transformed into MNI space) was used to determine the boundary
between the cerebrospinal fluid (CSF) and hippocampus for improved consis-
tency.
Estimated total intracranial volume (etotal intracranial volume (TIV))
was measured using Freesurfer [Buckner et al., 2004].
6.2.4 Hippocampal shape analysis
The hippocampal regions generated by manual segmentation were used to
analyse differences in shape between the subject groups. In this study spher-
ical harmonic (SPHARM) decomposition was used to represent hippocampal
shape. Arbitrarily shaped but simply connected objects can be decomposed
into a weighted series of SPHerical HARMonics (SPHARM) basis functions.
SPHARM shape decompositions have the advantage of encapsulating both
global and local shape features compactly. The SPHerical HARMonics - Point
Distribution Models (SPHARM-PDM) (Spherical Harmonics-Point Distribu-
tion Model) toolbox was used to calculate the coefficients of the SPHARM
basis functions of the hippocampi [Styner et al., 2006]. Any structure with
spherical topology can be represented by a weighted sum of spherical harmonic
(SPHARM) functions. For a perfect representation of the original shape an
infinite number of SPHARM basis functions would be required. In practice,
the number of SPHARM basis functions used to represent the original shape
is determined by a user-defined parameter “Lmax,” the maximum degree of
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the SPHARM expansion. The greater Lmax is, more basis functions will be
used in the representation and the finer the surface representation becomes.
Various values of Lmax were tested on a subset of hippocampi and visually
inspected. We chose to set Lmax=12 as we felt that this provided a sufficient
amount of detail.
The processing steps were as follows:
1. The hippocampi, that had been manually segmented in MNI space
at an isotropic resolution of 1 mm, were binarized and resampled to
an isotropic resolution of 0.5 mm. Interior holes were filled and a
minimal smoothing operation was applied to ensure spherical topol-
ogy (Fig 6.1a) [Styner et al., 2006]. As described by [Styner et al.,
2006], the smoothing was a two-step process: first a binary closing
operation was applied followed by anti-aliasing smoothing. The anti-
aliasing smoothing operation used in the SPHARM-PDM package (ITK
filter itk::AntiAliasBinaryImageFilter) smooths out jagged boundaries
but uses the original binary surface as a constraint ensuring minimal
loss in detail or structure (the smoothed surface is guaranteed to be
within ±3 voxels of the original surface) [Whitaker, 2000].
2. These pre-processed binary segmentations were then transformed into
raw surface meshes and spherical parametrisations for each of the hip-
pocampal meshes were computed (Fig 6.1b).
3. From the raw surface meshes and their spherical parametrisations,
SPHARM (spherical harmonic) descriptions were computed and corre-
sponding triangulated surface meshes were generated (Fig 6.1c). These
were all visually checked against the original manual segmentations to
ensure that the segmentations were well represented by their SPHARM
decompositions.
4. The triangulated surface meshes were then aligned to one (randomly
selected) individual’s hippocampal mesh using Procrustes alignment
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(translation and rotation only) and the triangulated surface meshes were
then regenerated such that the vertices corresponded between each in-
dividual’s mesh and the chosen reference mesh of the single subject
(Fig 6.1d). This was done for left and right sides separately.
5. A mean mesh was calculated from the aligned meshes (including the
individual reference mesh used for alignment in the previous step) and the
meshes were then aligned to the mean mesh using Procrustes alignment
and again the individual meshes were regenerated such that the vertices
corresponded between this mean mesh and each subject’s meshes. Again,
this was done for the left and right sides separately.
6. The meshes were loaded up side by side and the alignment was visually
checked for alignment failures.
7. Finally, the triangulated surfaces meshes were converted from Visual-
ization ToolKit (VTK) format to MNI object format and imported into
Matlab.
6.2.5 Statistics: demographics
Linear regression analysis was used to compare age (at the time of the scan)
between the diagnostic groups with age as the dependent variable and diagnos-
tic group (PCA, tAD or controls) as the independent variable. Fisher’s exact
test was used to compare the gender distributions between the groups. An
unpaired t-test was used to compare mini-mental state exam (MMSE) scores
between tAD and PCA subjects.
6.2.6 Statistics: brain and hippocampal volume analyses
Linear regression analysis was used to compare whole brain and hippocampal
volumes between the diagnostic groups. Brain or hippocampal volume was
the dependent variable, diagnostic group (PCA, tAD or controls) was the
independent variable and mean-centred age, gender and mean-centred head
size were adjusted for.
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Figure 6.1: Summary of shape analysis procedure: (a) Hippocampi are segmented,
holes filled and minimal smoothing applied, (b) raw surface meshes gen-
erated and spherical parametrisations are computed, (c) triangulated
surface meshes are computed from spherical parametrisations, (d) sur-
face meshes aligned (translation and rotation), (e) distance between
mean mesh and individual meshes at each vertice is calculated, (f) sta-
tistical comparisons performed.
6.2.7 Statistics: hippocampal shape analysis
The SurfStat toolbox for Matlab was used to perform statistical comparisons
on the hippocampal shapes [Worsley et al., 2009]. Two analyses on the hip-
pocampal shapes were performed. In the first analysis, the distance between
the surface of individual meshes and the mean mesh was the dependent vari-
able, disease group was the independent variable and mean-centred age, gender
and mean-centred head size were adjusted for. This was in order to visualise
where there were any shape or volume differences in PCA subjects as compared
to controls and typical AD. The second analysis was like the first analysis, but
mean-centred hippocampal volume was adjusted for, instead of mean-centred
head size. This was in order to visualise shape differences that were not due to
volume differences. Additional analyses were run adjusting for mean-centred
MMSE score and mean-centred disease duration as well as mean-centred age,
gender and mean-centred head size for the PCA v tAD comparisons in order
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to determine whether the differences observed in these comparisons were inde-
pendent of these measures of disease severity. All comparisons were corrected
for multiple comparisons (family wise error (FWE) correction). Maps showing
where there were significant differences in hippocampal surface morphology
were generated along with effect size maps.
6.2.8 Classification of subjects using hippocampal shape fea-
tures
To quantify the extent to which hippocampal shape differences described group
differences soft-margin support vector machine (SVM)s [Cortes and Vapnik,
1995] were used. The python package sci-kit learn, was used for this pur-
pose [Pedregosa et al., 2011]. To find out whether SPHARM coefficients were
better able to distinguish groups than hippocampal volume alone two SVMs
were used for each group-wise comparison, one with the SPHARM coefficients
as features and the other using just the left and right hippocampal volumes as
features. Each subject had a total of 1014 SPHARM coefficients (from both the
left and right hippocampi) since decomposition up to degree 12 was used. A
nested cross-validation approach was taken whereby the sample was split into
10 mutually exclusive stratified sets of approximately equal size. Figure 6.2
summarizes the nested cross-validation process used. The classifier was trained
and evaluated 10 times, once with each of the folds (data splits) as the test
set and the remaining data used for training. In order to determine the best
kernel (linear or radial basis function (RBF)) and kernel parameters, a grid
search and stratified 10-fold cross-validation was used (experimental evidence
suggests 10-fold cross-validation is the best method for model selection [Ko-
havi, 1995] on the training data each time. This sample splitting for kernel
parameter choice was performed in order to avoid over-fitting the data. Once
the kernel and hyperparameters were tuned, the resulting SVM was fitted to
the training data. Finally, the SVM was used to predict the labels of the test
set on which the SVM was not trained. This process was repeated for each
of the 10 folds. The same folds for the SVM with SPHARM coefficients were
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used as features and for the SVM with hippocampal volumes in order to be
able to make comparisons. The accuracy (proportion of correctly classified
subjects), sensitivity (proportion of true positives), and specificity (proportion
of true negatives) were then calculated. The area under the receiver operator
curve (ROC) curve (AUC) and f-score statistics are reported since they both
have advantages over accuracy when assessing the performance of a classifier.
The area under the curve (AUC) takes into account the decision value of the
classifier which accuracy ignores. The f-score is appropriate for imbalanced
classes (where one class is under-represented compared to another) and so is
a better measure of the performance of a classifier than accuracy. Accuracy,
sensitivity, and specificity are the same whether computing across all folds
or whether taking the average of each of the folds. The AUC and f-measure
are different however when computing across all folds or when averaging over
the folds. Previous work suggests that taking the mean AUC of each of the
cross-validation folds and computing the f-score across all folds (as opposed to
averaging) are less biased [Forman and Scholz, 2010]. Therefore, mean AUC
and f-score over all folds are reported in this study. Finally, in order to de-
termine whether the SVM using the SPHARM coefficients was significantly
better or worse at classification than the SVM using hippocampal volumes as
features, the McNemar test [McNemar, 1947] was used since it has been shown
to have a low type-1 error [Dietterich, 1998]
6.3 Results
6.3.1 Participant demographics
A total of 124 subjects were included in this study. See table 6.1 for a sum-
mary of participant demographics. The mean age of tAD subjects was higher
by approximately 5 years than in controls and PCA subjects (p<0.02 in both
comparisons). The mean MMSE scores was lower in tAD subjects than PCA
subjects (p=0.01). There was no difference in disease duration or gender dis-
tributions between the diagnostic groups (p>0.4, both tests).
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Figure 6.2: Nested 10-fold cross-validation procedure used for model tuning and
evaluation.
Table 6.1: Participant Demographics
Controls (n=48) PCA (n=47) tAD (n=29) P-value
Age (years) 63.6 (9.7) 63.0 (7.0) 68.3 (8.4) 0.02 a
% Male 31% 40% 45% 0.5 b
MMSE score/30 N/A 21.2 (4.6) 18.3 (4.5) 0.01 c
Disease duration (years) N/A 4.9 (2.7) 5.3 (3.1) 0.6 c
a Regression analysis. b Fisher’s Exact Test. c Unpaired t-test.
Mean(SD) unless otherwise stated.
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6.3.2 Brain and hippocampal volume analysis
Both PCA subjects and tAD subjects had significantly smaller mean adjusted
brain volumes than the controls (p<0.001) but there was no significant differ-
ence in mean adjusted brain volume between the PCA subjects and the tADs
(p=0.3). PCA subjects were found to have significantly smaller mean adjusted
hippocampal volumes on both the right and left sides as compared to controls
(p ≤ 0.002, both comparisons) (see table 6.2). They were however significantly
larger than those seen in tAD subjects (p ≤ 0.001, both comparisons).
6.3.3 Hippocampal shape analysis
6.3.3.1 Comparison of PCA and controls
Significant differences in surface morphology were seen between PCA subjects
and controls when adjusting for age, gender and head size: these were largely
confined to the posterior hippocampus with inward deformations in the hip-
pocampal tail region on both the right and left sides of the PCA subjects
compared to controls (see the blue regions in Figure 1a). Significant inward
deformations remained in the hippocampal tail regions of PCA subjects when
adjusting for hippocampal volume rather than head size effectively identify-
Table 6.2: Brain and hippocampal volumes (adjusted for age, gender and head-size)


















3.3 [3.2, 3.4] 3.0 [2.9, 3.2] 2.6 [2.4, 2.7]
a p≤0.001 as compared with controls. b p≤0.001 as compared with PCA.
Mean [Confidence Interval]
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ing areas of focal loss or deformation over and above the global hippocampal
volume loss (see blue regions in Figure 2a).
6.3.3.2 Comparison of PCA and tAD
Outward deformations in the mean right and left hippocampal surfaces of PCA
subjects were seen compared with tAD in large areas across the whole of the
hippocampus (see yellow/red regions in Figure 1c). There were only very small
regions where the mean surface of the tAD subjects had a significant outward
deformation compared to PCA (see blue regions in Figure 1c). When adjusting
for hippocampal volume rather than TIV no significant differences remained on
the right side but significant differences in hippocampal shape were still seen in
the left hippocampus in the left superior body with PCA outwardly deformed
compared to tAD (see Figure 2c). The hippocampal shape differences observed
between PCA and tAD subjects appear to be independent of disease severity
as adjusting for MMSE score and disease duration made very little difference
to the deformation patterns observed (see Figure 3).
6.3.3.3 Comparison of tAD and controls
In tAD, large areas of the mean left and right hippocampal surfaces were
inwardly deformed as compared to controls when adjusting for age, gender and
head size (see Figure 1b). The mean tAD hippocampal surface was inwardly
deformed with respect to controls in most areas (see the blue regions in Figure
1b) with some small regions where there was an outward deformation of the
mean surface in tAD compared to controls (see the red/yellow regions in Figure
1b). When adjusted for hippocampal volume however, only a small region of
significant difference survived in the superior medial left hippocampal tail (see
Figure 2b) and there were no significant differences on the right side.
6.4 Disease classification using SPHARM coefficients
The accuracies, sensitivities, specificities, mean AUCs, f-scores for each of
the SVMs are shown in table 6.3. In the PCA-control comparison, by us-
ing SPHARM coefficients only a classification accuracy of 77% was achieved
6.4. Disease classification using SPHARM coefficients 97
Figure 6.3: Hippocampal shape difference after adjusting for age, gender, and TIV
in (a) PCA vs. controls, (b) tAD vs. Controls, (c) PCA vs. tAD. The
colour scale for statistical difference represents the FWE-error corrected
P-values at a threshold of P=0.05. Blue indicates areas where there was
an inward deformation in (a) PCA as compared to tAD, (b) tAD as
compared to controls, (c) PCA as compared to tAD whereas red/yellow
indicates areas where there was an outward deformation. A=anterior,
P=Posterior.
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Figure 6.4: Hippocampal shape difference after adjusting for age, gender, and hip-
pocampal volume in (a) PCA vs. controls, (b) tAD vs. Controls, (c)
PCA vs. tAD. The colour scale for statistical difference represents the
FWE-error corrected P-values at a threshold of P=0.05. Blue indicates
areas where there was an inward deformation in (a) PCA as compared
to tAD, (b) tAD as compared to controls, (c) PCA as compared to tAD
whereas red/yellow indicates areas where there was an outward defor-
mation. A=anterior, P=Posterior.
6.4. Disease classification using SPHARM coefficients 99
Figure 6.5: Hippocampal shape difference in PCA vs. tAD after adjusting for (a)
age, gender, MMSE score, disease duration, and head size and (b) age,
gender, MMSE score, disease duration, and hippocampal volume. The
colour scale for statistical difference represents the FWE-error corrected
P-values at a threshold of P=0.05. Blue indicates areas where there was
an inward deformation in PCA as compared to tAD whereas red/yellow
indicates areas where there was an outward deformation. A=anterior,
P=Posterior.
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compared to 56% when using hippocampal volume information alone. McNe-
mar’s test showed that the SVM classifier using SPHARM coefficients signif-
icantly outperformed the classifier using hippocampal volumes (p=0.002). In
the Controls-tAD and PCA-tAD comparisons hippocampal volume alone was
able to classify subjects as accurately as the SPHARM coefficients.
Table 6.3: Comparison of performance of SVM classifer using SPHARM coefficients
vs SVM classifier using left and right hippocampal volumes as features)
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6.5 Discussion
PCA subjects had significantly reduced (8% lower) mean adjusted hippocam-
pal volumes (adjusted for age, gender and head size) compared to controls; It
is interesting to note that the PCA subjects had relatively preserved episodic
memory function despite this volume loss. The shape analyses pointed to the
differences in surface morphology in PCA being relatively localised posteriorly
with inward deformations seen in the hippocampal tail regions in comparison
with controls.
The loss of hippocampal volume in PCA was much lower than that seen in
typical amnestic AD (25% smaller hippocampi than controls). PCA subjects
had significantly larger hippocampal volumes than tAD subjects and that was
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reflected in the shape differences reported. When adjusting for age, gender and
head size, large areas of outward deformations, likely representing regions of
relatively preserved hippocampal tissue, were found in PCA subjects compared
to tAD; these were mostly seen in the superior hippocampal body with some
more minor differences in the tail and the head portion of the subiculum.
When hippocampal volume was adjusted for rather than head size, some
significant shape differences were still seen in PCA subjects as compared to
tAD (PCA>tAD) over a small area in the left hippocampus. Given that the
majority of difference was removed by adjusting for hippocampal volume it
is unsurprising that SPHARM coefficients did not aid in the classification of
PCA subjects from tAD.
To my knowledge, this is the first study to report shape differences in
the hippocampi of PCA subjects. These results suggest that although the
hippocampi in PCA subjects are relatively preserved as compared to tAD,
there is some tissue loss occurring in the hippocampi of PCA subjects compared
with controls. The tissue loss appears to be most significant in the superior
lateral hippocampal tail region, fitting with the posterior pattern (or gradient)
of atrophy seen in these subjects. In addition, when adjusting for hippocampal
volume, significant differences in surface morphology were still seen in PCA
subjects. Consistent with this, the hippocampal SPHARM coefficients were
better able to classify PCA subjects from controls than volume alone. Taken
together these data indicate that there is a distortion of the shape of the
hippocampi in PCA, which could be due to focal atrophy in the hippocampus
as well as the tissue to which it is connected. Although the exact functional
organisation of the hippocampus remains unclear, it has been suggested that
the posterior hippocampus supports detailed, context-rich spatial [Hirshhorn
et al., 2012] and autobiographical [Addis et al., 2004] memories, whilst the
anterior hippocampus supports more ‘gist’-like memories [Strange et al., 2014].
To date there has been no detailed characterization of memory function in
PCA, but the present findings of a posterior-anterior gradient of hippocampal
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volume loss and shape change may predict qualitative as well as quantitative
distinctions between memory processes in PCA and tAD.
As expected, significantly reduced hippocampal volumes were found in the
tAD subjects as compared to controls: widespread significant inward deforma-
tions were seen across large areas of both the right and left hippocampi in tAD.
Although it is difficult to precisely locate these inward deformations with re-
spect to hippocampal subfields, in tAD these seem to approximate to the CA1
subfield as well as the anterior and posterior subiculum. A number of previ-
ous studies have compared hippocampal shapes in tAD and controls [Gerardin
et al., 2009, Li et al., 2007, Lindberg et al., 2012, Shen et al., 2012, Thompson
et al., 2004]. These findings are in keeping with two previous studies that found
inward deformations in tAD subjects across large areas of the both the left and
right hippocampi [Gerardin et al., 2009, Shen et al., 2012]. One study found
large areas of inward deformations on the left hippocampus, particularly in the
hippocampal head as well as the superior tail region but found no differences
in the right hippocampus [Li et al., 2007]; another study reported localised in-
wards deformations in the hippocampal head in tAD subjects, particularly on
the left side [Thompson et al., 2004] whilst another study found some inward
deformations in the body of the left hippocampus and a small area of inward
deformation on the medial part of the right hippocampal head [Lindberg et al.,
2012]. Differences in the numbers of subjects, disease severities, shape analysis
methods and hippocampal segmentation methods used may account for some
of the different findings in these studies. When adjusting for hippocampal vol-
ume, no significant differences in shape were found on the right hippocampus
and only a small region in the superior medial portion of the hippocampal
tail on the left hippocampus. One other study [Shen et al., 2012] also inves-
tigated shape differences where the effect of volume was removed and, as in
this study, found significant shape differences in the posterior hippocampus.
The fact that most of the differences in shape were removed when adjusting
for hippocampal volume suggests that in tAD there was generalized, diffuse
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tissue loss across the whole of the hippocampus. Indeed, in this comparison,
the SPHARM coefficients did not aid in the classification of tAD subjects from
controls.
The fact that shape metrics helped separate PCA patients from controls
suggests that they may be useful in addition to volume and could be explored
in other diseases where diagnosis is difficult and subtle differences in atrophy
patterns exist. In this study, shape metrics were no better than hippocampal
volumes at distinguishing tAD subjects from controls. However, it is possi-
ble that the hippocampus does not atrophy uniformly during the tAD disease
course. Indeed, previous studies have shown that the CA1 subfield is dis-
proportionately affected in early AD [Che´telat et al., 2008, Csernansky et al.,
2005, La Joie et al., 2013, Mueller et al., 2010, Pluta et al., 2012, Wang et al.,
2006] and that hippocampal subfields or hippocampal shape may be more
sensitive at distinguishing mild cognitive impairment (MCI) or very mild AD
subjects from controls than whole-hippocampal volume [Csernansky et al.,
2005, La Joie et al., 2013, Mueller et al., 2010, Pluta et al., 2012]. Therefore
SPHARM coefficients may prove to be more useful at distinguishing controls
from tAD an earlier disease stage.
This study has a number of strengths. First the hippocampi were seg-
mented manually, including the full extent of the structure from tail to head.
Secondly, although PCA is an atypical variant of AD, there were a reasonable
number of cases to include in these analyses. The mean MMSE score was lower
in the tAD subjects than in the PCA subjects, this reflects the weighting of the
questions towards memory and orientation and the relative lack of questions
relating the visual deficits experienced by PCA subjects. Brain volumes in
the PCA and tAD subjects were not significantly different however suggesting
similar levels of overall brain atrophy between the groups.
There were several limitations to this study that warrant discussion. First,
the SPHARM-PDM pipeline requires that the shapes being analysed have
spherical topology. In the case of one of the hippocampi from one of the sub-
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jects with tAD, the SPHARM-PDM processing failed, perhaps because this
hippocampus did not have spherical topology (this subject was therefore ex-
cluded from all analyses and from the demographics table). It could be that the
failure rate is higher when comparing subjects with particularly pronounced
atrophy or by use of automated techniques where borders of the hippocam-
pal masks may not adhere to the spherical topological description. Secondly,
some smoothing was applied to the segmented regions before the spherical pa-
rameterization. Therefore, it may be that some of the differences that do in
fact exist are not found using this method since they have been attenuated.
Thirdly, pathological confirmation of AD was only available in 5 of the PCA
subjects and it may be that some of the remaining PCA subjects actually
have a different underlying disease [Crutch et al., 2012]. Fourthly, the type of
registration is an important consideration in interpreting the results regarding
localisation of tissue loss in any comparison. Other registration methods may
align hippocampi differently and therefore localise deformations in other ar-
eas. Fifthly, the MRI scans used in this study were from a retrospective cohort
with some variety in the scan parameters and in-plane resolutions; ideally, all
subjects would have identical imaging parameters. Although it is unlikely that
this would materially affect the results presented here, it cannot be excluded
as a possibility and further studies using consistant imaging parameters would
be required to confirm these findings. Sixthly, the images used were of limited
resolution compared with the high-resolution temporal lobe imaging which is
achievable [Winterburn et al., 2013]. Given that the hippocampi are relatively
small structures it may be that using higher resolution scans would enable the
detection of more subtle shape differences between groups. Finally, caution
is required when interpreting the results from shape analysis studies - a re-
cent study indicated that the SPHARM-PDM method of shape analysis might
overestimate regions of significant difference [Gao et al., 2014]. Stringent sta-
tistical methods (family-wise error correction) were used in order to minimise
false detection of differences where there were in fact none.
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In conclusion, the hippocampal region is affected in PCA at a relatively
early stage of the disease when memory is relatively preserved and produces
posterior shape changes. Reduced hippocampal volumes were found in PCA
subjects as compared to controls - intermediate between controls and tAD.
Whereas the macroscopic differences between tAD and control subjects were
governed by volume rather than shape, as were the differences between PCA
and tAD, most of the differences between PCA and controls are governed
by shape differences (PCA smaller in the tail). This was further evidenced
by shape (SPHARM) coefficients that were better able to distinguish healthy
controls from PCA subjects than hippocampal volume alone suggesting that






The automated hippocampal segmentation methods used to segment the hip-
pocampi in chapters 4 and 5 both utilized the same template library of man-
ually segmented hippocampi, described in detail in [Barnes et al., 2008]. The
use of this template library in combination with the Similarity and Truth Es-
timation for Propagated Segmentations (STEPS) algorithm has been shown
to have a good mean segmentation accuracy as compared to gold standard
manually-segmented regions [Cardoso et al., 2015] with a mean dice score of
0.925 achieved using leave-one-out cross-validation. Details of the STEPS al-
gorithm are given in chapter 3.
One limitation of this template library is that the protocol used for the
manual hippocampal segmentations did not include the hippocampal tail re-
gion. The quality of segmentations in the tail region varies significantly when
using this template library for automated segmentations (see figure 7.1). There
is no biological plausibility for the volumes on these slices so this variation can
only add noise to the volume measurements. There is evidence to suggest
that at least some parts of the hippocampal tail [Franko´ and Joly, 2013,Tang
et al., 2015] are affected by atrophy in typical Alzheimer’s disease and that
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it is particularly affected in atypical forms of Alzheimer’s disease (AD) such
as posterior cortical atrophy (PCA) (see chapter 6). Using a template library
that includes the full extent of the hippocampal tail in the manual segmenta-
tion protocol may improve the sensitivity of automated hippocampal volumes
as a marker of disease. In addition, a recent international initiative, the hip-
pocampal harmonization project, aimed to define a standard protocol for the
manual segmentation of the hippocampus. Expert collaborators from around
the world were involved in this project and agreed that the hippocampal tail
should be included in the standard segmentation protocol [Boccardi et al.,
2015b].
The aim of this study was therefore to investigate whether disease group
classification (AD vs controls and mild cognitive impairment (MCI) vs con-
trols) could be improved with the use of an alternative template library which








Figure 7.1: Example of the first three coronal slices of an automated hippocampal segmentation generated from the template library




7.2.1.1 Template library 1
Template library 1 consisted of the manual segmentations described in [Barnes
et al., 2008] and used in [Cardoso et al., 2015], those which did not include the
full extent of the hippocampal tail. Manual segmentations of both right and
left hippocampi (on T1-weighted magnetic resonance imaging (MRI) scans) for
a total of 55 subjects were included in this template library: 33 with clinically
diagnosed sporadic AD and 19 age matched healthy controls. See table 7.1
for a breakdown of the ages and genders of subjects used in template library
1. All manual segmentations were performed on scans registered to standard
space.
Table 7.1: Demographics of subjects included in template library 1
Controls (n = 19) AD (n = 36)
Mean (SD) age in years 69 (7) 70 (7)
Sex (M:F) 9:10 14:22
All subjects were scanned on a 1.5T Signa MRI scanner (General Elec-
tric, Milwaukee) using an inversion recovery sequence. All the scans used in
template library 1 had a voxel size of 0.9mm3.
7.2.1.2 Template library 2
Template library 2 consisted of manual segmentations which included the full
extent of the hippocampal tail. Manual segmentations of the hippocampi (on
T1-weighted MRI scans) for a total of 128 subjects were included in this tem-
plate library: 30 with sporadic typical amnestic AD, 47 with PCA, 1 with fa-
milial AD, 2 with subjective memory complaints (worried well) and 48 healthy
controls. Details of this cohort of subjects are given in 3.1.4. All manual
segmentations were performed on scans registered to standard space.
The controls and the subjects with amnestic AD and PCA were included
in the study in chapter 6. All subjects included in this template library were
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64 (10) 69 (9) 63 (7) 63 (N/A) 77 (N/A)
Sex (M:F) 15:33 13:17 19:28 2:0 1:0
N/A not applicable
scanned on a 1.5T Signa MRI scanner (General Electric, Milwaukee). There
was a range of voxel sizes for the scans used in template library 2 (see chapter
3), but the majority had a voxel size of 0.9mm3.
7.2.1.3 Test data
To test for differences in the ability of the two template libraries to dis-
criminate between controls and subjects with AD and MCI, baseline ac-
celerated T1-weighted scans from a total of 834 subjects from Alzheimer’s
disease neuroimaging initiative (ADNI)-2/GO were used (192 controls, 320
early mild cognitive impairment (EMCI), 172 late mild cognitive impairment
(LMCI) and 150 AD subjects). Accelerated scans were chosen over the non-
accelerated scans due to the finding, reported in chapter 4, that acceler-
ated scans suffer less from motion artefacts. All subjects in this study were
scanned on a 3T scanner (details of MRI protocols used can be found here:
http://adni.loni.usc.edu/methods/documents/mri-protocols/). See chapter 3
for details on the ADNI-2/GO cohort.
7.2.2 Hippocampal segmentation
7.2.2.1 Manual protocol used for template library 1
The segmentation protocol used for template library 1 is described in detail
in [Barnes et al., 2008]. Importantly the posterior limit of the hippocampus in
this protocol was defined as the coronal slice where the longest length of the
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crus of the fornix was visible. All scans and their flipped mirror images (in the
coronal plane such that the right side appeared on the left) were included as
templates along with their associated segmentations, resulting in a template
library of 110 hippocampal segmentations.
7.2.2.2 Manual protocol used for template library 2
A modification to the protocol used for template library 1 was made such
that the full extent of the hippocampal tail was included in the segmentation.
Briefly, the segmentation was continued on coronal slices posterior to coronal
slice where the longest length of the crus of the fornix was visible, follow-
ing the boundary between the grey and white matter inferiorly. Any visible
white matter of the fornix was excluded and care was taken not to include
the thalamus when it came into view. The most posterior slice was where
the hippocampal tail was still clearly visible as an ovoid shaped grey matter
mass. Segmentations were then checked and edited using the sagittal view.
All scans and their flipped mirror images (in the coronal plane such that the
right side appeared on the left) were included as templates along with their
associated segmentations, resulting in a template library of 256 hippocampal
segmentations.
An example of a hippocampus manually segmented using protocol 1 and
protocol 2 is shown in figure 7.2.
7.2.2.3 Automatic segmentation
The STEPS algorithm was used to segment the hippocampi of the ADNI-2/GO
subjects using each template library. This resulted in a segmentation for each
hippocampus using template library 1 and using template library 2.
7.2.3 Validation of template library 2
In order to test the reproducibility of template library 2, a leave-one-out cross
validation was performed. The scans (original and flipped) and corresponding
segmentations for each subject were removed from the template library in
turn, and the remaining scans used to automatically segment the hippocampi
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(a) (b)
Figure 7.2: Sagittal cross-section through a hippocampus segmented manually using




To compare the classification performance when using template library 2 vs
template library 1, logistic regression and receiver operator curve (ROC) curve
analyses was used.
In the first model the automatically segmented left and right hippocampal
volumes generated from the template library 1 (without tails) normalized for
head-size, (by dividing hippocampal volume by head-size), were included as
covariates. In the second model, the automatically segmented left and right
hippocampal volumes generated from the template library two (normalized for
head-size), were included as covariates.
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7.3 Results
7.3.1 Leave-one-out cross validation of template library 2
When using a leave-one-out cross validation approach, a mean dice score of
0.918 (min: 0.838, max: 0.945) was achieved.
7.3.2 Disease group classification comparison
Figure 7.3 shows the ROC curves for the comparison of template libraries 1
and 2 for disease group classification. The area under the ROC curve was
greater when using hippocampal volumes from template library 2 compared
with template library 1 for AD vs controls (p=0.02) and LMCI vs controls
(p=0.001). There was no evidence of a difference in the area under the ROC

















0.00 0.25 0.50 0.75 1.00
1−Specificity
Template library 1 ROC area: 0.86 [0.82, 0.90]

















0.00 0.25 0.50 0.75 1.00
1−Specificity
Template library 1 ROC area: 0.69 [0.62, 0.75]

















0.00 0.25 0.50 0.75 1.00
1−Specificity
Template library 1 ROC area: 0.55 [0.50, 0.60]
Template library 2 ROC area: 0.56 [0.51, 0.61]
Reference
EMCI vs controls
Figure 7.3: Receiver operator curves for disease group classification using template
library 1 and template library 2. ROC area [95% confidence interval]
shown in legend. AD: Alzheimer’s disease, LMCI: late mild cognitive
impairment, EMCI: early mild cognitive impairment.
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7.4 Discussion
Cross-validation showed that template library 2 (which included the full extent
of the hippocampal tail) had a good mean segmentation accuracy when com-
paring automated to manually-segmented regions. The mean dice score was
0.918 for template library 2, marginally lower than that achieved with tem-
plate library 1 (0.925), but these are arguably not 100% comparable as each
were tested within their respective template libraries. Despite this, the use of
template library 2 had a higher classification accuracy of AD subjects from
controls and LMCI subjects from controls compared with the use of template
library 1. There was no difference between the two in terms of discriminative
ability in EMCI from controls.
Reasons for the improved ability of template library 2 to distinguish be-
tween AD and controls and LMCI and controls could be due to a number of
reasons. Firstly, the inclusion of the hippocampal tail in template library 2
may have reduced the noise of resultant segmentations. Secondly, the wider
variety of morphologies used in template library 2 (due to the increased num-
ber of subjects and a wider variety of disease phenotypes) could have meant
that for each new hippocampus to segmented, better matches could be made.
Finally, differences in scan quality between the two template libraries could
in part explain the improved results. Should scan quality be improved or a
better match to the ADNI-GO/2 scans, then this might have an impact on the
quality of the resultant segmentations..
This assessment has a number of limitations. The main limitation is that
conclusions as to whether the inclusion of the tail or the quality or morphologies
represented in the second template library, cannot be ascertained. In order to
establish this, a comparison using the same set of template scans with two
different sets of segmentations (with and without the hippocampal tail) would
be required.
However, it can be concluded that a significant improvement in disease
group classification was achieved by using template library 2 over template
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library 1.
In addition to improving disease group classification, the segmentations
used in template library 2 more closely match the segmentation protocol de-
scribed by the recent hippocampal harmonization project [Boccardi et al.,
2015b], where experts from around the globe came to a consensus on what
should be included in hippocampal segmentations. The findings in this chapter
suggest that template library 2 may be more appropriate for use in Alzheimer’s
disease studies than template library 1.
Chapter 8
Manual and automated thalamic
segmentation
8.1 Introduction
This thesis has so far focussed on the hippocampus and hippocampal atrophy,
a widely-established marker of Alzheimer’s disease.
The hippocampus, part of the limbic system, is important for the forma-
tion of long-term memories [Scoville and Milner, 1957]. Other structures in the
limbic system, such as the anterior thalamic nucleus, are also known to play
an important role in episodic memory [Child and Benarroch, 2013] and there
is evidence to suggest that the anterior thalamic nucleus is also affected by
Alzheimer’s disease pathology; Braak and Braak found that at post-mortem,
whilst most of the thalamic nuclei were relatively mildy affected by Alzheimer’s
disease pathology, the limbic nuclei contained numerous neurofibrillary tangles
and neurophil threads with the antero-dorsal nucleus severely affected [Braak
and Braak, 1991]. Previous imaging studies have shown reduced thalamic
volumes in subjects with Alzheimer’s disease [De Jong et al., 2008].
The thalamus is an important hub in the brain, relaying information from
different subcortical areas to the cortex. It is an ovoid structure in the dien-
cephalon, mostly consisting of grey matter. The internal medullary lamina, a
Y-shaped sheet of white matter, separates the thalamus into three main parts:
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the anterior nuclei, the medial nuclei and the lateral nuclei. The superior sur-
face of the thalamus is covered by a layer of white matter called the stratum
zonale and the lateral surface by the external medullary lamina.
As discussed in chapter 2, thalamic segmentation from T1-weighted im-
ages is challenging due to the typically poor image contrast between the tha-
lamus and some of its surrounding structures. Diffusion tensor imaging allows
for the visualisation of white matter tracts, and may provide complimentary
structural information with regards to thalamic boundaries.
The aims of this study were: 1) to investigate whether manual segmen-
tation reproducibility could be improved by using both coloured fractional
anisotropy maps and T1-weighted magnetic resonance imaging (MRI) scans
together as opposed to T1-weighted MRI scans alone, 2) to generate a tem-
plate library of manually-segmented thalami based on the segmentation proto-
col developed, for use in automated segmentation pipelines and 3) to test the
ability of an automated pipeline [Cardoso et al., 2015] to accurately segment




In order to generate a template library with a variety of brain morphologies a
range of subjects with a mixture of pathologies was selected. For this purpose,
data from the AVID and young onset Alzheimer’s disease (YOAD) studies
described in chapter 3 were used. A total of 73 subjects were included: 57
subjects from the YOAD cohort and 16 from the AVID cohort. Demographic
information by cohort and diagnostic group is given in table 8.1.










AVID1 Controls 3 68 [65,72] 30†[30,30] 2:1
SD 4 68 [57,79] 23†[18,26] 2:2
PNFA 4 68 [64,70] 15†[6,30] 1:3
PCA 3 59 [57,62] 17 [13,23] 1:2
LPA 2 65 [59,72] 28† 2:0
YOAD Controls 20 60 [48,68] 30 [28, 30] 8:12
PCA 11 61 [53,70] 22 [13, 29] 3:8
tAD 25 61 [51,73] 21 [13, 28] 10:15
FvAD 1 53 15 1:0
73 62 [48,79] 73 [6,30] 30:43
SD: semantic dementia, PNFA: progressive nonfluent aphasia, posterior cortical atro-
phy (PCA): posterior cortical atrophy, LPA: logopenic aphasia, typical Alzheimer’s
disease (tAD): typical amnestic Alzheimer’s disease, FvAD: subject with atypical
Alzheimer’s disease with a frontal presentation.
† MMSE score not available for one subject.
8.2.2 MRI scan acquisition and processing
For details on the MRI scan protocols used in this study see chapter 3. For
details on the diffusion tensor imaging processing pipeline used to generate the
coloured fractional anisotropy (FA) maps, see chapter 3.
All subjects included in this study had both T1-weighted and diffusion
tensor imaging scans acquired in the same session. All T1-weighted scans were
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aligned to Montreal Neurological Institute (MNI) space and FA maps were
resampled in the space of the T1-weighted scans.
8.2.3 Manual segmentation protocol
A manual segmentation protocol of the thalamus was developed with refer-
ence to atlases [Duvernoy, 2005, Mori et al., 2002] and a previously published
thalamic segmentation protocol [Power et al., 2015].
A coronal section through the thalamus with the surrounding structures
labelled is shown in figure 8.1, fiigure 8.2 shows an axial section. The thalamus
is bounded medially by cerebrospinal fluid, laterally by the internal capsule and
inferiorly by the red nucleus.
Figure 8.1: Coronal slice showing the location of the thalamus and it’s surrounding
structures. Photographed and labelled by Dr. Bruce Crawford and Kurt
McBurney at the University of Victoria. This photograph is licensed
under a Creative Commons Attribution-Noncommercial-Share Alike 2.5
Canada License.
All manual segmentations were performed using the NiftyMidas software
tool (see chapter 3). This tool allows for the simultaneous visualization in all
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Figure 8.2: Axial slice showing the location of the thalamus and it’s surrounding
structures.Photographed and labelled by Dr. Bruce Crawford and Kurt
McBurney at the University of Victoria. This photograph is licensed
under a Creative Commons Attribution-Noncommercial-Share Alike 2.5
Canada License.
three planes whilst segmenting.
The anatomical landmarks used in the protocol developed in this study
were largely similar to those described in the protocol developed by [Power
et al., 2015]. In contrast to the protocol described in Power et al., the seg-
mentation was initiated in the axial plane in the protocol developed in this
study. In addition, a threshold of 70% of the mean brain intensity (derived
from whole brain segmentations) was used to delineate the cerebrospinal fluid
(CSF) from the thalamus.
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8.2.3.1 Practical guide to thalamic segmentation when using T1-
weighted scans only
In the most superior axial slices of the thalamus, the boundaries are defined
by the internal capsule laterally and CSF medially (see figure 8.3).
Figure 8.3: Three most superior axial slices through the thalamus (outlined in red).
The most superior slice is on the left through to the most inferior on the
right.
Moving inferiorly, the fornix comes into view, posterior to the thalamus.
Care was taken to exclude the most posterior white matter visible posterior to
the thalamus, which belongs to the fornix (using multiple views helped with
this) see figure 8.5.
Figure 8.4: Axial slice through the thalamus (outlined in red) where white matter
of fornix is visible posterior to the thalamus.
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Figure 8.5: Coronal, sagittal and axial view through an example brain with cross-
hairs indicating the fornix appearing as white matter posterior to tha-
lamus.
Segmentation was continued, following the CSF boundary medially and
the white matter boundary of the internal capsule laterally, on subsequent
inferior axial slices. When the habenula came in to view (figure 8.6) on the
medial side of the thalamus care was taken to exclude it from the segmentation.
Figure 8.6 shows the habenula in all 3 views.
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Figure 8.6: Coronal, sagittal and axial view through the thalamus with cross-hairs
indicating the habenula appearing as white matter medial to thalamus.
Soon after the habenula is visible, the superior colliculus, medial to the
thalamus, becomes visible, and care was taken to exclude this as well (see
figure 8.7).
Moving inferiorly, the red nuclei become visible (see figure 8.8). In slices
where the red nucleus was present, the top of the red nucleus, in coronal view,
served as a landmark for the inferior boundary of the portion of the thalamus
that is superior to the internal capsule.
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Figure 8.7: Axial section through brain showing location of superior colliculus with
respect to the thalamus (outlined in red).
Figure 8.8: Coronal, sagittal and axial view through thalamus with cross-hairs in-
dicating the top of the red nucleus, inferior to the thalamus.
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Moving inferiorly, the lateral geniculate body is still visible as a grey mass,
adjacent to the the cerebral peduncle in axial view (see figure 8.9). The lateral
geniculate nuclei are inferior to the internal capsule/cerebral peduncle and may
appear separated from the main mass of the thalamus in coronal view.
Figure 8.9: Axial slice through the brain at the level of the cerebral peduncle (indi-
cated by a white arrow). The lateral geniculate nuclei of the thalamus
are outlined in red.
Visualisation of the boundary between the internal capsule and thalamus
can be challenging in some scans and on some scan slices. Increasing the con-
trast between grey and white matter on the T1-weighted scans helps with the
visualisation of the boundary between the internal capsule and the thalamus.
Where the boundary is not clearly visible, slices superior and inferior to the
slice in question can be used to guide the placement of the boundary.
8.2.3.2 Practical guide to thalamic segmentation when using
coloured FA maps in addition to T1-weighted scans
When using coloured fractional anisotropy maps in addition to T1-weighted
scans, T1-weighted and coloured FA maps were overlaid in the window. In each
slice, the thalamus was first segmented using the T1-weighted map according to
the protocol outlined above, then the coloured FA map was used for refining
the internal capsule/thalamic boundary. An example of a T1-weighted and
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coloured FA map showing the boundary between the internal capsule and
thalamus on both is shown in figure 8.10. The coloured FA map was found
to be particularly useful for this purpose, but did not particularly aid in other
areas.
Figure 8.10: Axial slice through thalamus on T1-weighted scan (left) and coloured
FA map (right). The left thalamus is outlined in red and arrows indicate
the boundary between the internal capsule and thalamus, which can be
more easily visualised on coloured FA maps than on T1-weighted scans.
8.2.4 Testing reliability of manual segmentations
In order to test the reliability of the manual segmentation protocol, a subset
of 30 subjects from the YOAD dataset (10 with tAD, 10 with PCA and 10
controls) was selected. The left thalamus was segmented 4 times per subject;
twice using T1-weighted scans only and twice using T1 and FA maps. This
was performed in a random order and blinded to subject ID and diagnosis.
For half of the subjects, only the T1-weighted scan was presented first. For
the other half, both the FA map and T1-weighted scans were presented first.
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Scans were presented in such a way that the scans for a particular subject did
not get segmented more than once in the same day in order to prevent learning
bias. To compare the reliability of the segmentations, dice overlap scores, mean
surface distances and Hausdorff distances were calculated [Prados et al., 2017].
8.2.5 Testing reliability of automated segmentations
A leave-one-out cross-validation was performed using the template library of
manual segmentations generated and their associated MRI scans. The scans
(original and left-right flipped) and associated segmentations for each subject
were excluded from the template library in turn, and the remaining scans and
segmentations used to automatically segment the scan in question using the
Similarity and Truth Estimation for Propagated Segmentations (STEPS) algo-
rithm [Cardoso et al., 2015]. A brief description of how the STEPS algorithm
works is given in chapter 3. Dice overlap scores, mean surface distances and
Hausdorff distances between the manual segmentations for each subject and
the automatically segmented regions were calculated.
To test whether the automated segmentation pipeline performed better
with the inclusion of FA maps as compared with T1-weighted scans alone,
two separate leave-one-out cross-validations were performed. The first used
the labels with the T1-weighted scans only in the STEPS pipeline, the second
used the labels with the T1-weighted scans and the FA maps in the STEPS
pipeline.
8.3 Results
8.3.1 Reliability of manual segmentations
The mean dice score, mean surface distance and Hausdorff distance are shown
in table 8.2. In none of the comparisons was there a statistically significant
difference. When looking at all subjects combined, the use of FA maps in
combination with T1-weighted scans resulted in a marginally better mean dice
score and mean surface distance but a slightly worse Hausdorff distance com-
pared with T1-weighted scans alone. Higher dice scores and lower mean surface
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Table 8.2: Similarity metrics for repeated manual segmentations. Mean [95% confi-
dence interval] shown.















































































and Hausdorff distances were achieved in the control subjects than in either the
PCA or tAD groups, none of these differences reached statistical significance
however.
8.3.2 Reliability of automated segmentations
A summary of the results of the leave-one-out cross validation are shown in
table 8.3. The use of both T1-weighted scans along with FA maps resulted in
higher mean dice scores on both the right and left sides. The differences were
subtle, but reached statistical significance.
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Table 8.3: Similarity metrics for automated segmentations using T1-weighted scans
only vs manual segmentations and automated segmentations using FA
maps in addition to T1-weighted scans vs manual segmentations. Mean
[95% confidence interval] shown
T1 only T1 & FA map p-value
Left Dice 0.940 [0.937, 0.944] 0.942 [0.939, 0.945] 0.02
Mean surface
distance
0.334 [0.32, 0.348] 0.329 [0.316, 0.342] 0.02
Hausdorff
distance
2.295 [2.153, 2.437] 2.302 [2.141, 2.463] 0.87
Right Dice 0.941 [0.938, 0.944] 0.949 [0.947, 0.951] <0.001
Mean surface
distance
0.329 [0.317, 0.341] 0.299 [0.289, 0.308] <0.001
Hausdorff
distance
2.220 [2.105, 2.335] 2.081 [1.944, 2.218] 0.01
Examples of the best and worst automatic segmentation (according to the
dice overlap score) when using T1-weighted scans only is shown in figure 8.3.2
and when using FA maps in addition to T1-weighted scans is shown in figure
8.12. The scan with the biggest difference in dice overlap scores between the
region automatically segmented using T1-weighted scans only and the region
automatically segmented using both FA-maps and T1-weighted scans is shown
in figure 8.13.
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Figure 8.11: Best (top row) and worst (bottom row) automated segmentation (ac-
cording to dice score) when using T1-weighted scans only. Blue: in-
cluded in manual segmentation only, green: included in both manual
and automated segmentations, yellow: included in automated segmen-
tation only. The best segmentation had a dice score of 0.96 and the
worst had a dice score of 0.89.
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Figure 8.12: Best (top row) and worst (bottom row) automated segmentation (ac-
cording to dice score) when using FA maps and T1-weighted scans.
Blue: included in manual segmentation only, green: included in both
manual and automated segmentations, yellow: included in automated
segmentation only. The best segmentation had a dice score of 0.96 and
the worst had a dice score of 0.90.
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Figure 8.13: Scan with the biggest difference in dice scores between the automat-
ically generated thalamic region using T1-weighted scans (shown in
blue) and the automatically generated thalamic region using both FA
maps and T1-weighted scans (shown in yellow). The manually seg-
mented region is shown in green. The dice overlap between the man-
ually segmented region and the region automatically segmented using
T1-weighted scans only was 0.91 whilst for the manually segmented
region and the automatically segmented region using both FA and T1-
weighted scans it was 0.95.
8.4. Discussion 134
8.4 Discussion
Good levels of reproducibility were achieved when segmenting thalami us-
ing T1-weighted scans only and when using coloured FA maps in addition to
T1-weighted scans. Modest, but non-significant improvements in dice scores
and mean surface distance were seen when comparing the manual segmenta-
tions based on T1-weighted scans alone with those based on T1-weighted and
coloured FA maps.
The dice scores achieved from the automated segmentations in this study
(0.94 when using T1-weighted scans only and 0.95 when using FA maps in
addition to T1-weighed scans) were higher than dice scores reported in the
literature for the thalamus. The most widely used thalamic segmentation
method in AD studies, FIRST, reported a mean dice score of approximately
0.88 (number taken from graphical representation) [Patenaude et al., 2011].
The template library used by the FIRST algorithm includes scans from 336
subjects with range of pathologies, including Alzheimer’s diease, as well as
healthy controls. No information is given about the manual thalamic segmen-
tation protocol that was followed nor the field strength of the MRI scanners
used making comparisons difficult. The dice scores presented in this chap-
ter were also higher than those achieved when using the STEPS algorithm in
combination with a different template library 0.89 [Cardoso et al., 2015]. The
template library used in [Cardoso et al., 2015] was a set of 30 manually-labelled
brain scans from healthy volunteers aged between 20 and 54 years of age, de-
scribed in detail in [Hammers et al., 2003,Hammers et al., 2007]. A description
of the thalamic region definition used is given in [Hammers et al., 2003] and is
accordance with what was included in the protocol developed in this chapter.
Possible reasons for the superior dice score achieved in the study in this chap-
ter could be the larger size of the template library used, better scan quality
and tissue contrast (scans were acquired on 3T scanners in this study whilst
those used in [Cardoso et al., 2015] were acquired on a 1.5T scanner [Hammers
et al., 2003]) or more reliable manual segmentations (an example of one of the
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manually labelled brains is given in [Cardoso et al., 2015] and although the
slice shown does not include the thalamus, the regions shown appear to have
somewhat irregular and biologically implausible boundaries). In addition, a
modest, but statistically significant improvement in the mean dice score was
observed when using both FA maps and T1-weighted maps in the automated
pipeline as opposed to T1-weighted maps alone.
One recent study also utilized data from diffusion scans, in addition
to T1-weighted and T2-weighted scans, to automatically segment the tha-
lamus [Glaister et al., 2017]. In the method described by Glaister et al., a
thalamic region of interest is first obtained, by using a multi-atlas segmenta-
tion approach. A set of features, incorporating information from diffusion, T1
and T2-weighted scans is then computed at each voxel within the ROI. This
is then used to classify voxels as belonging to the thalamus, or not. Using this
technique, the authors reported mean dice scores of 0.88 and 0.89 for the left
and right thalami respectively, using leave-one-out cross validation. The dice
scores achieved in leave-one-out cross-validation in this chapter were higher
(0.94 using T1-weighted imaging only and 0.95 using FA-maps in addition to
T1-weighted imaging), although a head-to-head comparison of the two tech-
niques has not been performed.
In this study, a manual segmentation protocol with good reproducibil-
ity was developed. A template library of thalamic segmentations in subjects
with a range of pathologies was generated based on this protocol. The use of
this template library in combination with the STEPS algorithm was shown to
produce good quality automatic thalamic segmentations.
Chapter 9
Investigation into thalamic volume and
diffusion metrics in mild cognitive
impairment and Alzheimer’s disease
9.1 Introduction
As discussed in chapter 8, there is evidence that the thalamus may be affected
by Alzheimer’s disease pathology. Braak and Braak found that the antero-
dorsal nucleus was severely affected by Alzheimer’s disease pathology post-
mortem [Braak and Braak, 1991]. Imaging studies have shown reduced tha-
lamic volumes in subjects with Alzheimer’s disease [De Jong et al., 2008] and
studies in pre-symptomatic mutation carriers for familial Alzheimer’s disease
have shown diffusion changes in the thalamus prior to symptom onset [Ryan
et al., 2013]..
What is not known is at what stage in the disease process the thalami
are affected in sporadic Alzheimer’s disease, if there are thalamic diffusion dif-
ferences in subjects with sporadic Alzheimer’s disease (AD) and if diffusion
metrics are predictive of subsequent atrophy. This may aid early diagnosis of
disease and have implications for outcome measures of trials in early (preclin-
ical) AD.
The aims of this study were to:
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1. Investigate thalamic and hippocampal volumes in subjects with subjec-
tive memory complaints, early mild cognitive impairment, late mild cog-
nitive impairment and established Alzheimer’s disease. Hippocampal
volumes were used as a comparator to assess whether the thalamus is
affected at a similar stage to the hippocampus.
2. Investigate whether thalamic and hippocampal diffusion metrics can aid
in group differentiation above volumetric measures.
3. Investigate whether diffusion metrics are predictive of subsequent whole-
brain and hippocampal atrophy rates.
9.2 Methods
9.2.1 Study Participants
In this study, data from participants recruited to the the Alzheimer’s disease
neuroimaging initiative (ADNI)-GO and ADNI-2 phase of the ADNI study
(described in chapter 3) were used. All newly-enrolled subjects in the ADNI-
GO and ADNI-2 phases of the study were scanned on 3T magnetic resonance
imaging (MRI) scanners. All newly-enrolled subjects with T1-weighted imag-
ing were included in this study. A total of 973 subjects had accelerated T1-
weighted MRI scans available at baseline. Accelerated scans were chosen over
non-accelerated due to the findings reported in chapter 4. Subjects who were
scanned on General Electric (GE) scanners had diffusion imaging available in
addition to T1-weighted scans. A total of 218 subjects had both diffusion-
weighted and T1-weighted imaging available at baseline.
9.2.2 MRI Acquisition
Details of the MRI protocol used in this study can be found in chapter 3.
Diffusion weighted MRI scans were acquired in the same scanning session as
T1-weighted volumetric images for subjects scanned on GE scanners. Details
of the diffusion protocol and processing steps can be found in chapter 3.
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9.2.3 Quality control
All scans were assessed for motion and any with severe motion were excluded
from analyses.
9.2.4 Total intracranial volume, whole-brain, hippocampal and
thalamic region segmentation
total intracranial volume (TIV)’s were calculated using the method described
in chapter 3. Brains were segmented in native space using an automated
method described in chapter 3.4.1. Hippocampi were automatically segmented
using template library 2 as described in chapter 7. Thalami were automatically
segmented using the method described in chapter 8.
9.2.5 Extraction of diffusion metrics within regions-of-interest (
region of interest (ROI)s)
Both the thalamus and the hippocampus have boundaries with cerebrospinal
fluid (CSF). In order to ensure that the diffusion metrics in the regions-of-
interest were not biased by the inclusion of some CSF in the boundary voxels,
all regions were eroded once using a 3x3x3 voxel kernel, the smallest possible
sized kernel for symmetric erosion. All of the thalamic and hippocampal dif-
fusion metrics reported in this chapter are the mean diffusion metrics in those
eroded regions.
9.2.6 Whole-brain and hippocampal atrophy rates
Whole-brain and hippocampal atrophy rates were calculated using the methods
described in chapter 3.
9.2.7 Statistical Analyses
All statistical analyses were performed in Stata (version 12).
9.2.7.1 Baseline demographics
Linear regression with age as the dependent variable and diagnostic group as
the independent variable was used to compare age across diagnostic groups.
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Linear regression with bootstrapping was used to compare mini-mental state
exam (MMSE) scores across the diagnostic groups. Bootstrapping was used as
MMSE is not normally distributed and has a maximum value of 30. Differences
in the the proportions of male participants and apolipoprotein (APOE) ε4
carriers were compared across the diagnositic groups using chi-square tests.
9.2.7.2 Comparison of subjects in diffusion subset with full
ADNI-2/GO cohort
In order to acertain whether the group with diffusion imaging were a repre-
sentative subset of the whole dataset group characteristics between those who
had diffusion imaging available at baseline and those who did not were as-
sessed. Linear regression analyses were used to compare baseline age, brain,
hippocampal and thalamic volumes. Logistic regression was used to compare
percentages of males and APOE ε4 carriers and linear regression with boot-
strapping to compare baseline MMSE scores as this score has a ceiling effect
(subjects can score a maximum of 30).
9.2.7.3 Comparison of baseline volumes
In order to compare baseline whole-brain, thalamic and hippocampal volumes
between diagnostic groups linear regression analyses were used. The dependent
variable was the volume of interest with diagnostic group diagnostic group, age,
gender and head-size ( TIV) as independent variables.
9.2.7.4 Comparison of baseline hippocampal and thalamic dif-
fusion metrics
Linear regression analyses were used to compare baseline diffusion metrics
where the dependent variable was the mean diffusivity or fractional anisotropy
in the ROI with the independent variable being diagnostic group and the
models adjusted for age and gender. A second set of regression analyses were
fitted, additionally adjusting for the (non-eroded) volume of the ROI. This
was in order to see whether any significant differences by diagnostic group
remained after accounting for volume differences.
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9.2.7.5 Classification performance using diffusion metrics in ad-
dition to volumes
To investigate whether diffusion metrics improve diagnostic classification, lo-
gistic regression analyses were performed. Four binary variables were generated
for the different disease group comparisons: AD vs controls, LMCI vs controls,
early mild cognitive impairment (EMCI) vs controls and subjective memory
complaints (SMC) vs controls. These were then used as the dependent vari-
ables in the logistic regression analyses. In order to elucidate whether the use
of diffusion metrics in addition to volumetric measures improves diagnostic ac-
curacy two logistic regression models for each disease group comparison were
fitted, one with left and right hippocampal and thalamic volumes (divided
by TIV) and the other with left and right hippocampal and thalamic mean
diffusivity and fractional anisotropy metrics in addition to the normalised hip-
pocampal and thalamic volumes. To compare the ability of the models to
discriminate between cases and controls receiver operator curve (ROC) curves
were plotted and the area under the ROC curve for each model compared.
9.2.7.6 Predictors of subsequent atrophy
To investigate whether baseline diffusion metrics in the thalami and hip-
pocampi were associated with atrophy rates measured between baseline and
12 months, linear regression models were fitted with annualised whole-brain
or hippocampal atrophy rate (as a percentage of the baseline volume) as the
dependent variable, the diffusion metric of interest (mean diffusivity (MD) or
fractional anisotropy (FA) in the bilateral thalami or hippocampi) as the in-
dependent variable and adjusted for age and gender and diagnostic group. An
interaction term between diagnostic group and the diffusion metric of interest
was included to allow for differences in the effect of the diffusion metric on
atrophy rates between the diagnostic groups.
To investigate whether baseline hippocampal and thalamic volumes were
associated with atrophy rates measured between baseline and 12 months, linear
regression analyses were fitted with annualised whole-brain or hippocampal
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atrophy rate as the dependent variable, the volume of interest (left or right
hippocampal or thalamic volume) as the independent variable and adjusted for
age, gender, diagnostic group and TIV. An interaction term between diagnostic
group and the volume of interest was included to allow for differences in the
effect of baseline volume on atrophy rates between the diagnostic groups.
9.3 Results
9.3.1 Quality control
Of the 973 subjects who had data available for download at baseline, 943
had T1-weighted scans that passed internal dementia research centre (DRC)
quality control (QC) with 218 of these subjects having additional diffusion
weighted scans available.
Examples of scans which had levels of motion deemed unacceptable for
analysis are shown in figure 9.1. Examples of passing scans are shown in figure
9.2.
Figure 9.1: Examples of scans with motion artefacts severe enough for exclusion
from the study.
Figure 9.2: Examples of scans of good quality with little motion evident.
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One control subject was excluded from analyses as pathology was noted
in the left thalamus. This subject likely had an incidental thalamic arachnoid
cyst (see figure 9.3).
Figure 9.3: Subject with likely incidental arachnoid cyst in left thalamus. Arrows
indicate location of arachnoid cyst.
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9.3.2 Participant Demographics
Table 9.1 shows baseline characteristics by diagnostic group for all the ADNI-
2/GO subjects with T1-weighted scans available at baseline.
Table 9.1: Baseline characteristics of ADNI-2/GO cohort.










NL 193 73.2 (6.3) 29.0 (1.2) 54 29
SMC 105 72.2 (5.6) 29.0 (1.3) 58 33
EMCI 321 71.0 (7.4) 28.3 (1.5) 47 42
LMCI 173 72.2 (7.6) 27.6 (1.8) 46 58
AD 150 74.9 (8.0) 23.1 (2.1) 42 67
P-value <0.001a <0.001b 0.05c <0.001d
NL: controls, SMC: subjective memory complaints, EMCI: early mild
cognitive impairment, LMCI: late mild cognitive impairment, AD:
Alzheimer’s disease.
a linear regression
b linear regression with bootstrapping
c chi-square test
d chi-square test
218 subjects had diffusion available (32 NL, 26 SMC, 65 EMCI, 36 LMCI
and 48 AD). Figure9.4 shows a comparison of the baseline characteristics and
brain volumes between those who had diffusion imaging available at baseline
and those who did not. Those who had diffusion imaging available and were
diagnosed as EMCI were significantly older than those who did not have diffu-
sion imaging available at baseline. There was a significantly higher percentage
of APOE ε4 carriers in the late mild cognitive impairment (LMCI) group who
had diffusion imaging compared with those who did not. There were no signif-
icant differences in baseline MMSE scores or gender ratios between any of the
groups. Mean adjusted brain volumes were significantly smaller in the subset
of subjects with diffusion imaging available in controls, SMC, EMCI and AD
subjects than in those without, whilst there was no difference in baseline brain
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*adjusted for mean age, mean head−size and assuming an equal gender split
Baseline mean adjusted* brain volumes with 95% CIs
Figure 9.4: Comparison of baseline characteristics and volumes between those who
had diffusion imaging available at baseline and those who did not.
NL: controls, SMC: subjective memory complainers, EMCI: early mild
cognitive impairment, LMCI: late mild cognitive impairment, AD:
Alzheimer’s disease.
9.3.3 Baseline volumes
9.3.3.1 In the whole dataset
When comparing volumes in the whole group, mean adjusted whole-brain vol-
umes were found to be significantly smaller in LMCI and AD subjects as com-
pared to controls, whilst there was no significant difference in brain volume
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in EMCI subjects or SMC subjects with respect to controls. Mean adjusted
hippocampal volumes were significantly smaller in EMCI, LMCI and AD sub-
jects with respect to controls on both the right and left sides. Mean adjusted
thalamic volumes were also smaller in EMCI, LMCI and AD on the left side
and in LMCI and AD on the right side. Figure 9.5 shows the mean adjusted
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Left Thalamus Right Thalamus
*p≤0.05, **p≤0.01, ***p≤0.001 as compared to NL
γ adjusted for mean age, mean head−size and assuming an equal gender split
Figure 9.5: Baseline mean adjusted volumes in the full ADNI-2/GO cohort. Volumes
are adjusted for mean age, mean head-size and assume an equal gender
split. Error bars show 95% confidence intervals. Statistically significant
differences are represented by asterisks and represent differences with
respect to NL subjects. *p≤0.05, **p≤0.01, ***p≤0.001. NL=controls,
SMC=subjective memory complaints, EMCI=early mild cognitive im-
pairment, LMCI=late mild cognitive impairment, AD=Alzheimer’s dis-
ease.
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9.3.3.2 In the subset with diffusion imaging
In the subset of subjects who had diffusion imaging available at baseline, mean
adjusted whole-brain volumes were lower in the LMCI and AD subjects. Lower
hippocampal volumes were observed bilaterally in EMCI, LMCI and AD whilst
lower thalamic volumes were only observed in the AD group compared with
controls and no significant difference in volume was found between the LMCI,
EMCI or SMC groups and controls. Figure 9.6 shows the baseline volumes in
ADNI-2/GO subset with diffusion tensor imaging (DTI) imaging. Given the
imbalance in APOE ε4 carriers in the group with LMCI compared with the
whole dataset, post-hoc adjustment for APOE ε4 carrier status was performed,
but no significant differences to the findings were observed. The results pre-
sented in figure 9.6 are without adjustment for APOE ε4 as fewer subjects had
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*p≤0.05, **p≤0.01, ***p≤0.001 as compared to NL
γ adjusted for mean age, mean head−size and assuming an equal gender split
Figure 9.6: Baseline mean adjusted volumes in the subset of subjects with diffusion
imaging available. Volumes are adjusted for mean age, mean head-size
and assume an equal gender split. Error bars show 95% confidence
intervals. Statistically significant differences are represented by aster-
isks and represent differences with respect to NL subjects. *p≤0.05,
**p≤0.01, ***p≤0.001. NL=controls, SMC=subjective memory com-
plaints, EMCI=early mild cognitive impairment, LMCI=late mild cog-
nitive impairment, AD=Alzheimer’s disease.
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9.3.4 Diffusion metrics
Significantly higher mean adjusted (for age and gender) MD values were ob-
served in the left hippocampus in EMCI and LMCI subjects as compared with
controls and in both the left and right hippocampi in AD subjects as compared
with controls. When adjusting for hippocampal volume in addition to age and
gender, EMCI subjects had significantly higher hippocampal mean diffusivity
on left-side as compared with controls and AD subjects had significantly higher
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α adjusted for mean age and assuming an equal gender split
β adjusted for mean age, mean volume (left or right hippocampus) and assuming an equal gender split
*p≤0.05 compared with controls
Figure 9.7: Mean MD in left and right hippocampus. Error bars show 95% confi-
dence intervals.
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Subjects with SMC had slightly elevated mean adjusted MD in both the
left and right thalami compared with controls, although the differences did not
reach statistical significance. EMCI subjects had an elevated mean adjusted
MD in the thalami and the difference was statistically significant on the right
side and borderline significant on the left side (p=0.055). LMCI subjects had
slightly elevated MD values as compared to controls, although the differences
were smaller than in EMCI subjects and were not statistically significant. AD
subjects again had slightly elevated MD values as compared with controls, and
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α adjusted for mean age and assuming an equal gender split
β adjusted for mean age, mean volume (left or right thalamus) and assuming an equal gender split
*p≤0.05 compared with controls
Figure 9.8: Mean MD in left and right thalamus. Error bars show 95% confidence
intervals.
There was no significant difference in mean adjusted FA values in the
left or right side hippocampi in any diagnostic group (see figure 9.9). In the
thalamus, AD subjects had significantly increased mean adjusted FA values






















NL SMC EMCI LMCI AD NL SMC EMCI LMCI AD































NL SMC EMCI LMCI AD NL SMC EMCI LMCI AD









α adjusted for mean age and assuming an equal gender split
β adjusted for mean age, mean volume (left or right hippocampus) and assuming an equal gender split
*p≤0.05 compared with controls
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α adjusted for mean age and assuming an equal gender split
β adjusted for mean age, mean volume (left or right thalamus) and assuming an equal gender split
*p≤0.05 compared with controls
Figure 9.10: Mean FA in left and right thalamus. Error bars show 95% confidence
intervals.
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9.3.5 Disease classification using diffusion metrics in addition to
volumetric metrics
When comparing classification performance of hippocampal and thalamic vol-
umes alone or with additional diffusion metrics, it was found that classification
performance was improved with diffusion metrics (hippocampal and thalamic
FA and MD). This was significant in EMCI vs. controls and AD vs. controls.
A comparison of the ROC curves with and without diffusion metrics are shown
in figure 9.11. Table 9.2 summarizes the mean area under the ROC curve for
each comparison.
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Table 9.2: Area under ROC curves [95% confidence intervals]. *p≤0.05 as compared
with Model 1. Model 1: variables included left and right hippocampal
and thalamic volumes (normalised for head-size). Model 2: variables
included left and right hippocampal and thalamic MD and FA values in
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Figure 9.11: ROC curve comparison for disease group classification. Model 1, shown
in blue, used left and right hippocampal and thalamic volumes (nor-
malised for head-size) as predictor variables. Model 2, shown in red,
included left and right hippocampal and thalamic diffusion metrics (FA
and MD) in addition to the volumetric metrics included in Model 1.
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9.3.6 Predictors of atrophy rate
In controls, increased bilateral hippocampal MD at baseline was associated
with higher rates of hippocampal atrophy (an increase in hippocampal MD of
1 standard deviation was associated with a 2.2%/year increase in hippocam-
pal atrophy rate, p=0.04). No significant association was found in the other
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Figure 9.12: Baseline hippocampal MD vs hippocampal atrophy rate
In EMCI subjects, there was borderline evidence that increased baseline
bilateral thalamic MD values were associated with lower rates of whole-brain
atrophy (an increase in thalamic MD of 1 standard deviation was associated
with a 0.25% decrease in whole-brain atrophy, p=0.051). See figure 9.13. No
significant associations were found in the other diagnostic groups (p>0.5).
Increased bilateral thalamic FA at baseline was associated with increased
subsequent whole-brain atrophy in subjects with EMCI (an increase in thala-
mic FA of 1 standard deviation was associated with an increase of 0.28%/year
whole-brain atrophy rate, p=0.009), but not in any of the other disease groups
(p>0.1). Baseline hippocampal FA metrics were not associated with whole-
brain atrophy rates in any disease group (p>0.2).
Lower baseline left and right hippocampal volumes were associated with
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Figure 9.14: Baseline thalamic FA vs whole-brain atrophy rate
evidence that lower baseline left and right hippocampal volumes were associ-
ated with higher rates of hippocampal atrophy in EMCI and LMCI subjects
(p=0.06 for both). Baseline thalamic volumes were not associated with either
hippocampal or whole-brain atrophy rates in any of the disease groups.
9.4 Discussion
In this chapter thalamic and hippocampal volume and diffusion differences in
subjects with SMC, EMCI, LMCI and AD were investigated using the ADNI-
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2/GO dataset.
In the whole dataset, as expected, reduced hippocampal volumes were
found in AD, LMCI and EMCI subjects. Thalamic volumes were significantly
smaller in AD and LMCI subjects than in controls on both left and right sides
and were significantly smaller than controls on the left side in EMCI subjects.
In the subset with diffusion imaging, hippocampal MD values were higher
in AD, LMCI and EMCI than controls on the left side and higher in AD than
controls on the right side. In the thalamus, MD values were slightly higher in
EMCI and LMCI on the left side (trend level p<0.1) and in EMCI subjects on
the right side (trend level p< 0.1). When adjusting for volume, some of the MD
diffusion differences remained, suggesting that diffusion is providing different
information compared with macroscopic T1-weighted volume differences. FA
appeared to be a less promising measure in terms of group differentiation: there
were no significant differences in the hippocampi and or the thalami (although
thalamic FA values were slightly higher in AD subjects compared with controls
on the left side, p=0.06). In terms of diagnostic value, there was evidence
that diffusion metrics aided group differentiation in EMCI, LMCI and AD.
Diffusion metrics also aided in group differentiation in SMC compared with
controls although the difference in the area under the ROC curve did not reach
statistical significance. Higher baseline MD in the hippocampi was associated
with increased hippocampal atrophy rates in controls. It may be that the this
represents the effects of normal ageing in this group of individuals, or possibly
it could be an indication of very early dementia in those with higher baseline
hippocampal MD, although further studies would be required to confirm this
hypothesis. In EMCI subjects higher baseline thalamic FA was associated
with higher whole-brain atrophy rates and there was borderline evidence that
lower baseline thalamic MD was associated with higher rates of whole-brain
atrophy whereas baseline thalamic volumes were not. These findings suggest
that diffusion markers are useful prognostic markers early in the disease course.
As expected, we found hippocampal volume to predict volume loss in LMCI
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and EMCI subjects. However, extrapolating results from the diffusion subset
to the whole of ADNI is problematic since there was also evidence that this was
not a random subset: age differed in EMCI, APOE carrier numbers differed
in LMCI.
There were some discrepancies in thalamic volume findings between the
subset and the full ADNI2/GO cohort. Only the AD group showed signifi-
cantly reduced mean adjusted thalamic volumes at baseline in the diffusion
subset whilst reduced thalamic volumes were also seen in mild cognitive im-
pairment (MCI) subjects in the full ADNI2/GO cohort. Only subjects who
were scanned on GE scanners had DTI imaging available. Differences in base-
line volumes between those scanned on GE scanners and those scanned on
other scanners were found. This suggests that the subset with DTI imaging is
not a random sample of the full the full ADNI2/GO cohort and results must
be treated with necessary caution.
A number of previous studies have also reported reduced thalamic volumes
in AD [Steˇpa´n-Buksakowska et al., 2013,Yi et al., 2015,Mo¨ller et al., 2015,De
Jong et al., 2008]. In terms of thalamic volumes in MCI, two studies with
relatively small numbers of subjects (14 MCI subjects each) found singificantly
reduced thalamic volumes in MCI as compared with controls [Eustache et al.,
2016, Karas et al., 2004] as well a much larger, more recent study, with 201
MCI subjects [Yi et al., 2015]. The findings in this chapter are in keeping with
these previous studies.
In the hippocampi, mean diffusivity was significantly higher in all disease
groups as compared with controls whilst in the thalamus mean diffusivity was
significantly higher in EMCI as compared with controls. Qualitatively, the
relationship between disease stage and MD in the hippocampus and thalamus
differ. MD in the hippocampus was higher with increased disease severity.
MD in the thalamus was slightly higher in the early disease stages and rela-
tively lower at later disease stages. These qualitative differences contrast with
the largely similar volume patterns in both the hippocampus and thalamus
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(later disease stages were associated with lower volumes). One previous study
reported increased MD in the thalamus in AD compared to MCI (but they
found no difference in MD between AD and controls nor between controls and
MCI) [Cherubini et al., 2010]. Another previous study found no significant
difference in thalamic MD between MCI and controls [Eustache et al., 2016].
The finding that thalamic FA was slightly higher in AD subjects as com-
pared to controls (on the left side), but not significantly different in SMC,
EMCI or LMCI subjects, was in keeping with the literature. Previous studies
in familial AD have found increased FA in the thalamus in presymptomatic
mutation carriers [Ryan et al., 2013]. The thalamus is organised into distinct
nuclei with differing fibre orientations [Wiegell et al., 2003a]. If only specific
nuclei are affected, as suggested in the literature [Aggleton et al., 2016], it is
possible that the mean FA in the the thalamus as a whole actually increases.
Since a proportion of the individuals included in the SMC, EMCI and LMCI
groups will not go on to develop AD, it may be that the increased thalamic
FA in these disease groups is attenuated.
Increased baseline left and right thalamic FA was associated with in-
creased whole-brain atrophy at 12 months in subjects with EMCI and in-
creased baseline hippocampal MD was associated with higher hippocampal
atrophy rates in controls subjects. Previous longitudinal studies in subjects
with MCI have found those who went on to convert to a diagnosis of AD
had significantly higher MD in the hippocampi at baseline than those who did
not [Mu¨ller et al., 2007,Kantarci et al., 2010,Douaud et al., 2011]. It is possible
that increased baseline hippocampal MD could reflect a reduction in cellular
integrity and be a very early indication of neurodegeneration in these controls,
although to confirm this, a longer follow-up would be required in order to see
who goes on to convert to a diagnosis of MCI or AD.
There were a number of limitations to this study. Firstly, the diffusion
scans in the ADNI-2/GO cohort did not have field maps available, which may
have had an impact on the quality of the registration with the T1 weighted
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MRI scans. Secondly, this study was largely (apart from atrophy rates) cross-
sectional in nature. In order to get a better insight into the dynamic changes
occurring, in structures like the thalamus, a longitudinal study would be re-
quired. Thirdly, since the literature suggests that the anterior thalamic nuclei
are more severely affected than the medial or lateral thalamic nuclei, it would
be interesting to segment the thalami into sub-regions and investigate differ-
ences between the nuclei. This was not possible with the contrasts available
on the T1-weighted scans and the FA maps from this study. Finally, in order
to extract diffusion metrics that were not contaminated by voxels potentially
containing some CSF, thalamic and hippocampal regions were eroded by a
3x3x3 kernel. This may have had differential effects in the thalamus and hip-
pocampus; the thalamus is a relatively large ’bulb’ shaped structure, whilst
the hippocampus has a relatively thin body region. An erosion kernel of this
size may mean that the diffusion metrics obtained from the body region of the
hippocampus may only be coming from a limited number of voxels as a re-
sult. In order to overcome this limitation, it might be advantageous to instead
take a partial volumes approach, such as that described in [Eaton-Rosen et al.,
2016].
This study had a number of strengths. It was the largest study to date to
investigate thalamic volumes and diffusion metrics in AD and MCI subjects,
including EMCI subjects. In addition, a validated protocol for thalamic seg-
mentation was used, which had better segmentation reliability than methods
used in previous studies.
In summary, these findings give support to the hypothesis that the thala-
mus is implicated in Alzheimer’s disease relatively early in the disease course
and that diffusion metrics provide useful complimentary information to vol-
ume measures and may prove to be valuable in early diagnosis in Alzheimer’s
disease. In EMCI subjects, the inclusion of thalamic and hippocampal diffu-
sion metrics significantly increased the ability to classify EMCI subjects from
controls compared with volumetric measures alone.
Chapter 10
Investigation in to thalamic and
hippocampal volumes and diffusion
metrics in early-onset Alzheimer’s
disease
10.1 Introduction
As discussed in chapter 2, approximately 5% of those with dementia have an
age of onset below 65 years of age, with Alzheimer’s disease pathology being
the underlying cause in about a third of those with young-onset dementia.
Non-amnestic presentations are more common in young-onset Alzheimer’s dis-
ease (AD), including posterior cortical atrophy (PCA) and logopenic aphasia
(LPA) [Mendez et al., 2012]. Relatively little is known about the effects of
AD on subcortical regions in younger onset cases. Studying different presen-
tations gives better information about the different disease presentations of
young-onset AD. In addition to macrostructural differences, microstructural
differences may exist. This may lead to better biomarkers in the future for
these different presentations.
There is evidence to suggest that amyloid deposition is greater in the
thalami in young-onset Alzheimer’s disease than in late-onset Alzheimer’s dis-
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ease [Cho et al., 2013b] and that young-onset Alzheimer’s disease subjects
have increased glucose hypometabolism in the thalamus compared with con-
trols [Kim et al., 2005]. Lower thalamic volumes have been found in late-onset
Alzheimer’s disease [De Jong et al., 2008], and there is increasing evidence
that the thalamus may play an important role in early stages of late-onset
Alzheimer’s disease [Aggleton et al., 2016].
The aim of this study was therefore to investigate thalamic and hippocam-




The patients included in this chapter are described in chapter 3. Patients
were classified as having a typical [McKhann et al., 2011] (herein referred to as
typical Alzheimer’s disease (tAD) or atypical (posterior cortical atrophy [Tang-
Wai et al., 2004]) AD phenotype (herein referred to as PCA) according to
published criteria. Twenty-four age and gender matched control subjects were
also recruited.
10.1.1.2 Imaging
For details of the imaging protocol followed see chapter 3. Fractional
anisotropy (fractional anisotropy (FA)) maps and mean diffusivity (mean dif-
fusivity (MD)) maps were generated using the pipeline described in chapter
3.3.1.
10.1.1.3 Brain, thalamic, hippocampal and total-intracranial
volume segmentation
Brains were segmented using an automated method as described in chapter
3.4.1. Hippocampi were segmented using the automated method described
in chapter 7 with the template library which included the full extent of the
hippocampal tail. Thalami were segmented manually, with reference to both
the T1-weighted and registered colour FA maps, using the protocol described
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in chapter 8. Total intracranial volume (TIV) was extracted automatically
using the method described in chapter 3.
10.1.1.4 Extraction of thalamic and hippocampal diffusion met-
rics
The thalamic and hippocampal regions were eroded by a 3x3x3 voxel kernel
and mean diffusivity and fractional anisotropy scores were calculated within
the eroded regions. This was performed to ensure that boundary voxels which
included cerebrospinal fluid were excluded.
10.1.1.5 Statistical Analyses
Linear regression was used to compare baseline ages between the disease
groups. Linear regression with bootstrapping (200 repetitions) was used to
compare baseline mini-mental state exam (MMSE) scores. A chi-squared test
was used to compare gender ratios and t-test was used to compare disease
duration between the PCA and tAD groups.
To compare baseline volumes, linear regression analyses were used with
the volume of interest as the dependent variable and adjusting for diagnostic
group, age, gender and head-size (TIV ).
To compare baseline diffusion metrics, linear regression analyses were
used with the diffusion metric of interest (thalamic or hippocampal fractional
anisotropy (FA) or mean diffusivity (MD)) as the dependent variable and ad-
justing for diagnostic group, age and gender.
10.1.2 Results
10.1.2.1 Demographics
Table 10.1 shows the baseline characteristics of the subjects included in this
study.
10.1. Introduction 165
N Age MMSE % female Disease duration
Controls 20 59.8 (6.1) 29.5 (0.7) 60 n/a
PCA 11 61.4 (6.0) 22.1†(5.1) 73 4.3 (4.9)
tAD 25 61.2 (5.2) 20.7†(4.4) 60 5.0 (2.8)
Table 10.1: Baseline characteristic of local young-onset AD cohort. Mean (standard
deviation (SD) ) shown. †Significant difference with respect to controls
(p<0.05).
10.1.2.2 Brain, thalamic and hippocampal volume differences
Table 10.2 shows the mean-adjusted whole-brain volumes were significantly
smaller in the PCA and tAD groups as compared with controls. Mean-adjusted
right and left thalamic and hippocampal volumes were significantly smaller in
the tAD group compared with controls. Hippocampal and thalamic volumes
were intermediate to those in controls and in tAD on the right side in PCA
subjects, but the difference did not reach statistical significance. There was no

























































Table 10.2: Mean adjusted baseline volumes [95% confidence interval] by diagnostic
group. Volumes are adjusted for mean age, mean head-size and assume
an equal gender split.
10.1.2.3 Thalamic and hippocampal diffusion differences
Table 10.3 shows the results from diffusion imaging reporting the microstruc-
trual differences in the three groups. The PCA subjects had significantly
higher mean adjusted fractional anisotropy in both the left and right thalami
compared with control subjects but there was no difference in the left or right
hippocampal FA. Subjects with tAD had a significantly increased mean ad-
justed FA in the left thalamus but not in the right, and a significantly reduced
mean adjusted FA in both the left and right hippocampi as compared with
controls. Those with tAD also had significantly increased mean adjusted MD






























































































Table 10.3: Mean adjusted [95% confidence interval] FA and MD metrics in the left
and right thalamus and hippocampus. Metrics were adjusted for mean
age and assume an equal gender split.
10.2 Discussion
In this study, thalamic and hippocampal volumes were found to be significantly
smaller in young-onset AD subjects who presented with typical amnestic symp-
toms compared to controls. These subjects also had evidence of microstruc-
tural differences, with significantly higher left thalamic FA, significantly lower
right and left hippocampal FA and significantly higher right and left hippocam-
pal MD scores as compared with controls.
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In the early-onset AD subjects who presented with PCA, mean-adjusted
volumes in the right thalamus and right hippocampus were intermediate to
those seen in controls and those who presented with typical AD, but the dif-
ferences did not reach statistical significance. There was no evidence of volume
differences between controls and those with PCA in the left hippocampus or
thalamus. Although there was no statistically significant difference in hip-
pocampal or thalamic volumes in those with PCA compared with controls,
there was evidence of microstructural diffferences in both the left and right
thalami and the right hippocampus. Increased FA was observed in both the
right and left thalami and decreased FA in the right hippocampus.
Whilst a number of studies have investigated thalamic volumes in typical
late-onset Alzheimer’s disease (see chapter 9) only one study to date has specif-
ically investigated thalamic volumes in subjects with young-onset Alzheimer’s
disease. They found no difference at baseline between those with young-onset
AD and controls [Cho et al., 2013a]. Although they did not specify the dis-
ease presentation of the participants with young-onset AD in their study, there
were no statistically significant differences between the neuropsychological tests
scores of those with young-onset AD and those with late-onset AD in their
study, suggesting the majority of their young-onset AD cohort had an amnes-
tic presentation. The study had a relatively small number of participants with
early-onset AD (n=14) and may have been underpowered to find a difference
at baseline. However, they did find that thalamic volumes declined with time
in those with young-onset AD.
Although no statistically significant difference in hippocampal volume be-
tween PCA and control subjects was found in this study, they were somewhat
reduced on the right side. In chapter 6, PCA subjects were found to have
significantly lower mean adjusted hippocampal volumes than control subjects
on both the right and left sides and hippocampal volumes that were interme-
diate to those seen in controls and in typical AD. It may be that there was not
enough power in this study to find a difference as there were only 14 individu-
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als with PCA in this chapter, whilst in chapter 6 there were far more (n=47).
In addition, the subjects included in this study had a slightly higher mean
MMSE score and slightly lower mean disease duration than those included in
the study in chapter 6, so it may be that they were less advanced in their
disease course.
The findings in this chapter are also largely in accordance with those
in the Alzheimer’s disease neuroimaging initiative (ADNI) study reported in
chapter 9. The only groups that are truly comparable in a qualitative sense
are the control subjects and those with tAD. Similar to the findings in the
ADNI subjects reported in chapter 9, when the volume of the thalamus is
significantly lower in tAD, then there is some evidence of FA being higher. As
with the AD subjects in the ADNI cohort, there was no significant difference
in thalamic MD values in the tAD subjects. There are some differences in the
hippocampal diffusion findings between the two studies. Hippocampal FA was
not found to be significantly lower in the AD group in the ADNI study (who
had significantly atrophied hippocampi); in the tAD subjects in this study
hippocampal FA was lower on the left side. However, the hippocampal MD
values were significantly higher than in controls in both the AD subjects in
the ADNI study and in the tAD subjects in this study. The PCA subjects
cannot feasibly compared with any of the disease groups in the ADNI study.
They had higher thalamic FA values and higher right hippocampal MD values,
which does not fit with the patterns seen in any of the disease groups studied
in the ADNI cohort. FA and MD values were more similar to those seen
in the ADNI AD group than any of the disease groups, despite the lack of
thalamic volume differences in the PCA group. In other words - PCA is a
unique entity and understanding disease progression in this group will inform
us about AD in its variant forms. Further this will aid those with PCA through
better monitoring and prognostic information. Longitudinal studies would be
required to understand the dynamic diffusion and volumetric changes in PCA.
This is the first study to date to specifically investigate thalamic and
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hippocampal diffusion metrics in early-onset sporadic AD and the largest study
to date to investigate thalamic volumes in those with young-onset AD.
This study has a number of limitations. First, although MMSE scores
and disease durations were not significantly different between those with PCA
and tAD, neither are particularly good measures of disease severity in subjects
with PCA. Mean-adjusted brain volumes were similar in the PCA and tAD
groups however, suggesting similar levels of overall baseline atrophy. In this
study, only FA and MD differences were investigated. Participants in this study
also had neurite orientation dispersion and density imaging (NODDI) imaging
performed and NODDI metrics may provide greater insight into the diffusion
differences detected [Zhang et al., 2012]. This study was cross-sectional in
nature and longitudinal imaging would be required in order to verify that the
differences in volume and diffusion metrics are indeed pathological changes.
Finally, as mentioned in chapter 9 both the hippocampus and the thalamus
are complex structures making differences in diffusion metrics, particularly FA,
hard to interpret.
In summary, this study has shown reduced thalamic and hippocampal
volumes in subjects with amnestic young-onset AD as compared to controls
and microstructural changes in the thalamus and hippocampus in both amnes-
tic and PCA variants of young-onset AD. These findings give support to the
hypothesis that thalamus is affected by Alzheimer’s disease, even in the ab-
sence of significant thalamic atrophy and may provide both insight into disease
processes in differing variants and ultimately biomarkers to track progression.
Chapter 11
General Conclusions
This thesis has investigated, in depth, the effects of Alzheimer’s disease on the
hippocampus and thalamus in various disease presentations and at different
disease stages.
Accelerated T1-weighted scans were found to be equivalent to unaccel-
erated T1-weighted scans for assessing brain, ventricular and hippocampal
volumes and atrophy rates and fewer accelerated scans suffered from motion
artefacts than unaccelerated. This is important as it allows for more valu-
able time in the scanner for other sequences which may provide additional
information.
The hippocampus was found to be disproportionately affected by atro-
phy in apolipoprotein (APOE) ε4 carriers. This has implications for clinical
trials as it means that APOE ε4 status should be considered when using hip-
pocampal atrophy rates as outcome measures; APOE ε4 carrier status should
be adjusted for in statistical analyses. The hippocampus was also found to
be reduced in volume in the posterior cortical atrophy variant of Alzheimer’s
disease, despite a lack of memory deficits in these individuals. Atrophy was
found to be localised in the most posterior portion of the hippocampal tail in
these individuals. Hippocampal shape metrics were also found to be valuable
for disease classification and were superior to hippocampal volumes alone for
this disease group.
A new hippocampal template library, including the full extent of the hip-
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pocampal tail, for use in automated segmentation pipelines, was compared to
an existing, widely used hippocampal template library. The new template li-
brary achieved a good mean dice score in leave-one-out cross validation and
was better able to separate diseased subjects from controls than the existing
template library to which it was compared.
A set of manually-segmented thalamic regions were generated, using
multi-modal imaging, for use in automated segmentation pipelines. The
thalami and hippocampi of the Alzheimer’s disease neuroimaging initiative
(ADNI)-GO/-2 cohort were segmented using both the new thalamic and hip-
pocampal template libraries. Reduced thalamic volumes were observed in
those with Alzheimer’s disease, late mild cognitive impairment and in those
with early mild cognitive impairment (on the left side). This was the first
study to date to find lower thalamic volumes at the early mild cognitive im-
pairment stage, suggesting that in addition to the hippocampus, the thalamus
is implicated in Alzheimer’s disease early on in the disease course. Thala-
mic volumes in a cohort of young-onset Alzheimer’s disease subjects were also
investigated. This cohort included individuals with both posterior cortical at-
rophy and with typical amnestic Alzheimer’s disease. Thalamic volumes, in
addition to hippocampal volumes, were found to be significantly reduced in
those with amnestic Alzheimer’s disease. There was no evidence of thalamic
volume reductions in those with posterior cortical atrophy (PCA).
Hippocampal and thalamic diffusion metrics were also investigated in the
subset of ADNI-GO/-2 subjects that had diffusion imaging available and in
the young-onset Alzheimer’s disease (AD) cohort. No significant differences
in thalamic diffusion metrics were found between the disease groups in the
ADNI-GO/-2 cohort and controls, although there was borderline evidence for
higher mean diffusivity in the thalamus in early and late mild cognitive impair-
ment (MCI) subjects and borderline evidence for increased thalamic fractional
anisotropy (FA) values in subjects with AD. Hippocampal mean diffusivity
(MD) values were significantly higher in early MCI, late MCI and AD subjects
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on the left side and in AD subjects on the right side, compared with controls.
Diffusion metrics were found to significantly improve disease classification in
combination with volumetric measures, as compared to volumetric measures
alone when classifying early MCI vs controls, late MCI vs controls and AD vs
controls. There was also evidence that some diffusion metrics were predictive
of subsequent atrophy rates in control subjects and subjects with early mild
cognitive impairment (EMCI). In the young-onset AD cohort, the PCA group,
who had no evidence of thalamic atrophy, had significantly higher thalamic FA
than controls. Those with typical AD had increased FA in the left thalamus,
decreased FA in the left hippocampus and increased MD in both the left and
right hippocampi. Taken together these findings suggest that thalamic MD
may possibly increase before atrophy occurs and decreases as the thalamus
atrophies. Further MD in the hippocampus appears to increase with increas-
ing levels of atrophy. Longitudinal studies would be required to confirm these
hypotheses however.
In order for accurate early diagnoses, beneficial to both patients and car-
ers, there is a real need for multi-modal markers. Metrics such as those de-
scribed in this thesis may be useful in identifying those who are likely to
progress to a diagnosis of AD, when they are in the early MCI stage and lit-
tle cognitive function is lost. This may have implications in terms of either
inclusion criteria and/or outcome measures in clinical trials of very early dis-
ease. The thalamic and hippocampal segmentation libraries may be of use for
diagnosis and disease tracking.
In summary, the studies described in this thesis have extended current
knowledge of hippocampal and thalamic atrophy patterns and diffusion differ-
ences in Alzheimer’s disease and it’s variants, with important implications for
clinical trials of putative Alzheimer’s disease therapies.
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Chapter 13
Appendix: Statistical models used in
APOE ε4 study
13.1 Cross-sectional analysis
For the analysis examining the influence of the APOE ε4 allele on baseline
hippocampal volumes, the following linear regression model was used:
Yi=β0 +β1e4carrieri +β2agei +β3 f emalei +β4mmsei +β0TIVi + εi
and
εi ∼ N(0,σ2ε1)
Yi is the hippocampal volume for subject i, e4carrier is a categorical vari-
able representing the APOE epsilon4 carrier status (0 if non-carrier, 1 if car-
rier), age is the mean centred age, female is a categorical variable for gender
(0 if male, 1 if female), mmse is the mean centred MMSE score, brainTIVra-
tio is the mean centred brain to total intracranial volume ratio, TIV is the
mean centred total intracranial volume, εiis the error term, β0is the baseline
hippocampal volume in non 4-carriers, β1is the difference in volume between
non-carriers and carriers and β2,β3, ...,β6 are the fixed effects coefficients cor-
responding to the other covariates.
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13.2 Longitudinal analysis
For the analysis examining the influence of the APOE ε4 allele on rates of
hippocampal and whole brain atrophy the following joint mixed model was
used:
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Here Y (1)i j denotes the jth measurement of brain loss between baseline
and time ti j for subject i, and Y
(2)
i j the corresponding measure of hippocampal
loss. β (1)0 is the mean adjusted brain atrophy rate in non 4 -carrier males with
mean age, mean mmse score, mean brain-to-TIV ratio and mean headsize,
β (1)1 is the difference in mean adjusted brain atrophy rate between 4 carriers




6 are the fixed effect coefficients for the other
covariates (age, gender, MMSE score, brain-to-TIV ratio and TIV) for brain
loss and b1i is the random effect slope for subject i, likewise β
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adjusted hippocampal atrophy rate in non 4-carrier males with mean age,
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The covariance σε1ε2 allows the residual errors within visits to be corre-
lated for the two measures and the covariance σb1b2 allows the random slopes
to be correlated. This enables us to adjust the difference in hippocampal at-




ADNI Alzheimer’s disease neuroimaging initiative.
APOE apolipoprotein.
AUC area under the curve.





DLB dementia with Lewy bodies.
DRC dementia research centre.
DTI diffusion tensor imaging.
DWI diffusion weighted imaging.
EMCI early mild cognitive impairment.
FA fractional anisotropy.
FLAIR Fluid-Attenuated Inversion Recovery.
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FOV field of view.
FWE family wise error.
GE General Electric.
GM grey matter.
HMAPS hippocampal multi-atlas propagation and segmentation.
KN-BSI robust boundary shift integral.
LMCI late mild cognitive impairment.
LPA logopenic aphasia.
MAPS Multi-Atlas Propagation and Segmentation.
MCI mild cognitive impairment.
MD mean diffusivity.
MMSE mini-mental state exam.
MNI Montreal Neurological Institute.
MPRAGE Magnetization Prepared RApid Gradient Echo.
MRI magnetic resonance imaging.
NODDI neurite orientation dispersion and density imaging.
PCA posterior cortical atrophy.
PET positron emission tomography.
PNFA progressive nonfluent aphasia.
QC quality control.
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ROC receiver operator curve.
ROI region of interest.
SD standard deviation.
SMC subjective memory complaints.
SNR signal-to-noise ratio.
SPHARM SPHerical HARMonics.
SPHARM-PDM SPHerical HARMonics - Point Distribution Models.
STEPS Similarity and Truth Estimation for Propagated Segmentations.
SVM support vector machine.
tAD typical Alzheimer’s disease.
TIV total intracranial volume.
WMH white matter hyperintensities.
YOAD young onset Alzheimer’s disease.
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